(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

[US/SG]; c/o Agency for Science, Technology and Re-
search, 20 Biopolis Way, #07-01 Centros, Singapore
138668 (SG). WEI, Chialin [US/SG]; c/o Agency for
Science, Technology and Research, 20 Biopolis Way,
#07-01 Centros, Singapore 138668 (SG).

(54) Title: METHOD TO GENERATE OR DETERMINE NUCLEIC ACID TAGS CORRESPONDING TO THE TERMINAL ENDS OF DNA MOLECULES USING SEQUENCES ANALYSIS OF GENE EXPRESSION (TERMINAL SAGE)

(57) Abstract: We describe a method of providing
an indication of an instance of expression of a gene,
the method comprising the steps of (a) providing a
complementary deoxyribonucleic acid (cDNA) having
a terminus comprising a terminal transcribed sequence
of a gene; (b) linking the cDNA to an linker sequence
thereby forming a linked nucleic acid, in which the linker
sequence comprises a first recognition site for a first
nucleic acid cleavage enzyme, preferably a restriction
endonuclease, that allows nucleic acid cleavage at a site
distant from the first recognition site; and (c) cleaving
the linked nucleic acid with the first nucleic acid cleavage
enzyme to provide a linked tag, in which the linked tag
comprises a nucleotide sequence tag representative of
a terminal transcribed sequence of the gene; and (d)
detecting the presence or identity of the linked tag or the
nucleotide sequence tag to provide an indication of an
instance of gene expression.

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

METHOD TO GENERATE OR DETERMINE NUCLEIC ACID TAGS CORRESPONDING TO THE TERMINAL ENDS OF DNA MOLECULES USING SEQUENCES ANALYSIS OF GENE EXPRESSION (TERMINAL SAGE)

FIELD

The present invention relates to the field of biology, in particular, the fields of molecular biology, genomics, genome annotation, gene expression, transcriptome analysis
5 and diagnostics. In particular, the present invention relates to a method of Serial Analysis of Gene Expression (SAGE).

BACKGROUND

One the most burdensome tasks in the post genome-sequencing era is the accurate and complete annotation of all genes and their products, primarily mRNA transcripts of a
10 sequenced genome. Bioinformatics analyses of fragmentary experimental data have led to widely varying estimates of the number of human genes. Human EST assembly resulted in 89,000 Unigene clusters; *ab initio* genome annotation identified approximately 30,000 genes by two independent studies; and the manually curated RefSeq database has only 17,000 genes identified with stringent evidences. It is apparent that current technologies
15 applied for genome annotation including computational gene prediction, cDNA cloning and sequencing, and other new technologies are inefficient, incomplete, and unconvincing.

Computational methods including homology studies, domain searches, and *ab initio* gene predictions have great limitation and fallibility. Current prediction programs may be fine for many 'internal' exons, but perform particularly poorly on border exons in
20 UTR regions. They need to be trained by more experimental data. The precise annotation of every gene in complex genomes by computation methods alone is still a distant goal.

Although cDNA cloning and sequencing, including EST, full-length, and OFESTES, have generated immense data in EST and full-length cDNA sequences, low abundance and large size transcripts are discriminated against during cloning steps.
25 Library-based cDNA approaches are incomplete for identifying all transcripts due to high redundancy of abundant transcripts and high percentage of truncated clones. A

2

comprehensive cDNA library approach may be efficient for capturing the first 50-70% of all expressed transcripts, but it soon becomes prohibitively expensive and inefficient for getting the rest, in particular the rare transcripts.

5   Genome-wide scans by oligonucleotide microarrays provide another strategy that has the potential to help annotate complex genomes. In this approach, oligo probes representing predicted exons are synthesized, micro-arrayed, and subsequently hybridised to mRNA samples. Experimental data generated would provide validations to true exons. This approach is expected to be efficient to examine many different biological stages and environmental conditions for expressed transcripts. However, a major limitation of this

10   method is its ability to convincingly determine the existence of rare genes because the signal detection sensitivity of probe hybridization is limited.

Serial Analysis of Gene Expression (SAGE)

      Serial Analysis of Gene Expression (SAGE) represents a unique strategy to identify the existence of transcripts and quantify them by counting a small tag for each transcript

15   molecule in a complex transcriptome. Three principles underlie the SAGE methodology: (1) A short sequence tag (10-14bp) contains sufficient information to uniquely identify a transcript provided that that the tag is obtained from a unique position within each transcript; (2) Sequence tags can be linked together to from long serial molecules that can be cloned and sequenced; and (3) Quantitation of the number of times a particular tag is

20   observed provides the expression level of the corresponding transcript. The unique feature of SAGE is that a 14-bp sequence is enough to be transcript specific and small tags from each transcript can be extracted and concatenated into larger pieces for efficient sequencing analysis. Because of all transcripts are represented by small tags in same size, there is no discrimination in SAGE tag cloning. Essentially all transcripts should be

25   represented in SAGE tags.

      SAGE is described in US Patent numbers 5,695,937, 5,866,330 and 6,383,743, and is illustrated in Figures 1A and 1B, and also in Velculescu, V. E., Zhang, L., Vogelstein, B., and Kinzler, K. W. (1995). Serial Analysis Of Gene Expression. Science 270, 484-487,

as well as Velculescu, V. E., Zhang, L., Zhou, W., Vogelstein, J., Basrai, M. A., Bassett, D. E., Hieter, P., Vogelstein, B., and Kinzler, K. W. (1997). Characterization of the yeast transcriptome. Cell 88. A number of websites devoted to SAGE may also be consulted for teachings on this technique, including www.sagenet.org and http://www.ncbi.nlm.nih.

5   gov/sage (SAGEnet, a public gene expression data repository and online data access and analysis site, see Lash AE, Tolstoshev CM, Wagner L, Schuler GD, Strausberg RL, Riggins GJ, Altschul SF. (2000) SAGEmap: a public gene expression resource. Genome Res 2000 Jul;10(7):1051-60). Other websites describing SAGE and its uses may be found at http://www.google.com/search?sourceid=navclient&ie=UTF-8&oe=UTF-

10   8&q=Serial+Analysis+of+Gene+Expression

In brief, mRNA is obtained from a cell or tissue, and reverse transcribed to obtain cDNA (see Figure 1). The cDNA is then cleaved by a first restriction enzyme (the "Anchoring Enzyme", typically a 4-base cutter), and the 3' end of the cDNA is anchored to a bead. The beads are optionally divided into two pools, and the cDNA attached to the

15   beads is ligated to two sets of adaptors or linkers. Each of these adaptors comprises a defined nucleotide sequence for PCR priming and amplification at its 5' end, as well as a recognition site for a type IIS enzyme (the "Tagging Enzyme", for example BsmFI and FokI), which directs cleavage by the enzyme at a position 3' downstream of the recognition site. The tags are released by cleavage with the relevant Tagging Enzyme, and

20   ligated together end to end to form ditags. The ditags are then amplified using PCR, digested with the Anchoring Enzyme, and ligated together to form concatamers. Sequencing of the concatamers reveals the identity and frequency of the tags, and provides expression data for the various genes which are transcribed in the cell or tissue. Due to the efficiency of sequencing small tags, SAGE has the potential to capture all expressed

25   transcripts.

Despite these promises however, the original SAGE tags are too short for direct mapping to complex genomes. The 14-bp tags are only reliable for mapping onto existing EST or cDNA sequences in databases, or small genomes such as yeast. This shortcoming limits the application of SAGE to use only as an expression profiling tool, not for genome

annotation. To overcome this problem, the developers of the original method managed to make the SAGE tags longer, simply by taking the advantage of a new IIS enzyme MmeI that cleaves DNA 20 base pairs away from its recognition site. The modified method is known as LongSAGE, and is described in WO 02/10438. This modification makes the

5 LongSAGE tags specific enough to be directly mapped onto human chromosome sequences (Table 1 in **Appendix B**). This function is an important addition because new SAGE tags now can be directly marked onto specific chromosome locations for potential new genes or exons identifications, therefore, facilitating genome annotations.

However, despite its advantages, LongSAGE still has limitations to its effective

10 use. Like the original SAGE, LongSAGE tags are extracted randomly depending on where the NlaIII sites are in a transcript sequence, so providing only 'internal' sequence clues for new transcripts. Furthermore, the new SAGE tags identified have to go through very tedious and long process such as 5' and 3' RACE to extend the information about the existence and characteristics of new genes. Finally, only one tag is generated for each

15 expressed sequence, and it is not possible with the prior art methods to obtain further sequence information for the expressed gene readily.

The present invention seeks to solve these and other problems in the prior art techniques for expression analysis.

SUMMARY

20 We have realised that the prior art SAGE and LongSAGE techniques have disadvantages. In particular, we have recognised that particular disadvantages arise from the fact that the tags obtained in the prior art techniques reflect internal sequences of the expressed genes.

No one to our knowledge has appreciated the usefulness of obtaining sequence tags

25 from the 5' and 3' termini of transcripts. On the other hand, we have realised that such terminal tags have advantages in that they can be used to define the boundary regions of

5

genes. In addition, the full-length coding sequence of unknown genes may easily be obtained by PCR, once the sequence tags from the 5' and 3' termini of the transcribed region are known. Furthermore, obtaining a 5' terminal transcribed sequence in a tag can provide a handle for promoter identification, as described below.

5   We therefore provide methods and compositions for obtaining tags corresponding to 5' and 3' terminal transcribed sequences of expressed genes, i.e., tags corresponding to the 5' and 3' termini of transcripts. We also provide methods of obtaining further sequence information in the form of further sequence tags from expressed genes, which may be conduced in a repetitive or iterative manner.

10   According to a first aspect of the present invention, we provide a method of providing an indication of an instance of expression of a gene, the method comprising the steps of: (a) providing a complementary deoxyribonucleic acid (cDNA); (b) linking the cDNA to an linker sequence thereby forming a linked nucleic acid, in which the linker sequence comprises a first recognition site for a first nucleic acid cleavage enzyme,

15   preferably a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site; and (c) cleaving the linked nucleic acid with the first nucleic acid cleavage enzyme to provide a linked tag, in which the linked tag comprises a nucleotide sequence tag representative of a terminal transcribed sequence of the gene; and (d) detecting the presence or identity of the linked tag or the nucleotide sequence tag to

20   provide an indication of an instance of gene expression.

In a preferred embodiment, the 5' end of the cDNA comprises a sequence corresponding to the 5' terminal transcribed sequence of the gene, and the linker sequence is linked to the 5' end of the cDNA. Preferably, the nucleotide sequence tag comprises a 5' terminal transcribed sequence of the gene, preferably at least the first 16 bases of the

25   transcribed portion, more preferably the first 20 bases of the transcribed portion of the gene.

6

In a further preferred embodiment, the 3' end of the cDNA comprises a sequence corresponding to the 3' terminal transcribed sequence of the gene, and the linker sequence is linked to the 3' end of the cDNA. Preferably, the nucleotide sequence tag comprises a 3' terminal transcribed sequence of the gene, preferably at least the last 16 bases of the

5   transcribed portion, more preferably the last 20 bases of the transcribed portion of the gene.

Preferably, step (a) comprises: (i) deriving a cDNA from an mRNA by reverse transcription with an primer comprising a sequence 5'-NV(T)^{13}CCGGCCGG-3', in which N = A, C, G or T and V = A, C or G; (ii) producing a double stranded cDNA therefrom

10 and digesting the double stranded cDNA with FseI to produce a cleaved cDNA comprising

$$3' \frac{GGCCGG}{CC}$$ overhang; (iii) linking the cleaved cDNA to a linker

comprising $\frac{pTCGGA}{GGCCAGCCT}$; and (iv) cleaving the resulting molecule with MmeI to

produce a cDNA lacking a polyA/T tail.

In highly preferred embodiments, the cDNA comprises the 5' terminal transcribed

15 sequence of the gene, or the 3' terminal transcribed sequence of the gene, or both. Preferably, the cDNA is full length cDNA, preferably comprising substantially all the coding sequence of the gene. The cDNA may in some embodiments be processed such that it does not comprise any untranslated regions, such as 5' UTR and / or 3' UTR. Specifically, in preferred embodiments, the cDNA does not comprise a portion of,

20 preferably does not comprise the whole of, the polyA/T tail.

There is provided, according to a second aspect of the present invention, a method of obtaining sequential sequence information from a gene, the method comprising steps (a) to (c) of a method according to the first aspect of the invention, or any preferred embodiments, the method further comprising: (d) providing a second nucleic acid from

25 step (c) comprising 3' remaining sequences of the cDNA; (e) linking the second nucleic acid to an linker sequence, thereby forming a linked nucleic acid, in which the linker sequence comprises a recognition site for a nucleic acid cleavage enzyme, preferably a

7

restriction endonuclease, that allows nucleic acid cleavage at a site distant from the recognition site; (f) cleaving the linked nucleic acid with the nucleic acid cleavage enzyme to provide: (i) a linked tag comprising the linker sequence linked to a nucleotide sequence tag comprising a 5' portion of the second nucleic acid; and (ii) a fourth nucleic acid

5   sequence comprising a 3' remainder portion of third nucleic acid; (g) repeating steps (d) to (f) at least once, in which the second nucleic acid sequence of step (d) is provided by the fourth nucleic acid sequence of step (f)(ii); and (h) detecting the presence, identity or sequence of at least one linked tag or a nucleotide sequence tag comprised therein.

This aspect of the invention enables "walking" along the cDNA, i.e., the ability to

10   obtain a further nucleotide sequence tag comprising further sequence internal to the terminus, which is offset from the first nucleotide sequence tag initially obtained. Further rounds may be carried out to sequentially obtain further nucleotide sequence tags.

In preferred embodiments, the linker sequence further comprises a second recognition site for a second nucleic acid cleavage enzyme, preferably a second restriction

15   endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site, and in which the second recognition site is located 5' of the first recognition site in the linker sequence.

In such embodiments, the location of the second recognition site with respect to the first recognition site may be such that, when the linked tag is exposed to the second

20   nucleic acid cleavage enzyme, cleavage of the nucleic acid occurs at a position within or about the first recognition site.

Preferably, the first recognition site or the second recognition site, or both, comprises a Type IIS restriction enzyme recognition site.

Preferably, the first recognition site comprises a Mmel recognition site 5'-TCC

25   RAC-3', preferably 5'-TCC GAC-3'. Preferably, the second recognition site comprises a BseRI recognition site 5'-GAGGAG-3'.

8

Preferably, the linker sequence comprises the sequence 5'-
<u>GAGGAG</u>NNNNNNTC CG AC -3', preferably 5'-<u>GAGGAG</u>CGTCTC<u>TCCGAC</u>-3'.

We provide, according to a third aspect of the present invention, a method of
detecting expression of a gene, the method comprising: (a) providing a first linked tag and

5   a second linked tag, each independently produced by a method according to the first or
second aspect of the invention, including preferred embodiments; (b) linking the first
linked tag and the second linked tag such that the nucleotide sequence tag portion of one
linked tag is linked to the nucleotide sequence tag of the other linked tag to form a ditag,
the ditag comprising terminal transcribed sequences from first and second genes; and (c)

10   detecting the presence or identity of the ditag, or at least one nucleotide sequence tag
comprised therein, to detect gene expression.

Preferably, each of the first linker sequence of the first linked tag and the second
linker sequence of the second linked tag comprises an amplification primer hybridisation
sequence. Accordingly, in preferred embodiments, the method further comprises a step of

15   amplifying the ditag, preferably by means of the polymerase chain reaction (PCR).

Preferably, the method further comprises the step of cleaving the ditag with the or
each second nucleic acid cleavage enzyme to provide a trimmed ditag.

The trimmed ditag may comprise between 12 to 120 base pairs, preferably between
18 to 46 base pairs, preferably 40 base pairs.

20   Preferably, a plurality of ditags or trimmed ditags are linked to form a concatamer.
The concatamer may comprise between 2 to 200 ditags or trimmed ditags, preferably
between 8 to 20 ditags or trimmed ditags.

The method may further comprise the step of determining the sequence of a or each
linked tag, nucleotide sequence tag, ditag, trimmed ditag or concatamer. A further step of

25   determining the identity of the expressed gene by the comparing the sequence to a

nucleotide sequence comprised in a database of nucleotide sequences may also be included. The sequence may be compared to a database of known genes, such that if the database does not comprise the sequence, the sequence comprises a new gene.

As a fourth aspect of the present invention, there is provided a method of
5   providing an indication useful in the diagnosis of a disease in an individual, the method comprising: (a) providing a cell known to be affected by the disease; (b) determining if a gene is expressed in the cell of (b) by a method according to any preceding aspect of the invention; (c) providing a cell of an individual suspected of suffering from the disease; and (d) determining whether the same gene is expressed in the cell of (c) by a method
10   according to any preceding aspect of the invention; and (e) comparing the expression, or lack thereof, of the gene between the cell of (b) and the cell of (c).

The present invention, in a sixth aspect, provides a method of producing determining the transcriptome of a cell, or obtaining a gene expression profile of a cell, the method comprising providing cDNA from the cell, subjecting said cDNA to a method
15   according to any preceding aspect of the invention, and determining whether a particular gene, or a particular set of genes, is expressed by the cell.

In a seventh aspect of the present invention, there is provided a method of providing an indication useful in the diagnosis of a disease in an individual, the method comprising comparing the gene expression profile of a cell known to be affected by the
20   disease, with a cell of an individual suspected of suffering from the disease, in which either or both of the gene expression profiles are produced by a method according to sixth aspect of the invention.

According to an eighth aspect of the present invention, we provide a method of determining the sequence of a control sequence of a gene, preferably a promoter or
25   enhancer sequence, the method comprising: (a) obtaining a nucleotide sequence tag representative of the 5' terminal transcribed sequence of the gene by a method according to the first aspect of the invention, or any preferred embodiments; and (b) obtaining a

sequence of the gene 5' to the terminal transcribed sequence of (a) comprising a promoter or enhancer consensus sequence.

In a preferred embodiment, the sequence of the gene 5' to the terminal transcribed sequence of (a) is obtained by means of (a) chromosome walking, (b) SAGE walking, (c)

5   nucleic acid hybridisation of a genomic library; or (d) querying a database of genomic sequences.

We provide, according to a ninth aspect of the invention, a database comprising a plurality of records, each record comprising an indication whether a gene is expressed by a particular cell, which indication is provided by a method according to any preceding aspect

10   of the invention.

There is provided, in accordance with a tenth aspect of the present invention, a computer readable medium comprising a database according to the ninth aspect of the invention.

As an eleventh aspect of the invention, we provide nucleic acid sequence

15   comprising a tag produced by a method according to any preceding aspect of the invention.

We provide, according to a twelfth aspect of the invention, there is provided a nucleic acid sequence comprising a ditag produced by a method according to any preceding aspect of the invention.

According to a thirteenth aspect of the present invention, we provide a nucleic acid

20   sequence comprising a concatamer comprising a plurality of such tags or such ditags.

There is provided, according to a fourteenth aspect of the present invention, a gene identified by a method according to any preceding aspect of the invention, or a protein encoded by the gene.

A control sequence, preferably a promoter sequence, identified by a method according to any preceding aspect of the invention.

According to a thirteenth aspect of the present invention, we provide a nucleic acid sequence comprising: (a) a recognition site for a nucleic acid cleavage enzyme, preferably

5   a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site, and (b) a nucleotide sequence tag representative of a terminal transcribed sequence of a gene.

The nucleic acid sequence may further comprise: (c) a second recognition site in which the second recognition site is for a second nucleic acid cleavage enzyme, preferably

10 a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site, and in which the cleavage site for the second nucleic acid cleavage enzyme is located within or about the first recognition site.

Alternatively, or in addition, the nucleic acid sequence may further comprise: (c) a second recognition site 5' of the first recognition site, in which the second recognition site

15 is for a second nucleic acid cleavage enzyme, preferably a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site, and in which the first recognition site and the second recognition site are spaced such that when the nucleic acid is exposed to the second nucleic acid cleavage enzyme, cleavage of the nucleic acid occurs at a position within or about the first recognition site.

20   We further provide a linker sequence comprising: (a) a first recognition site for a nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site; (c) a second recognition site for a second nucleic acid cleavage enzyme, preferably a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site; in

25 which in which the cleavage site for the second nucleic acid cleavage enzyme is located within or about the first recognition site.

Preferably, the nucleic acid sequence comprises the sequence 5'-
GAGGAGNNNNNNTC CG AC -3', preferably 5'-GAGGAGCGTCTCTCCGAC-3'.

According to a fourteenth aspect of the present invention, we provide a method for
detecting expression of a gene, the method comprising the steps of: (a) providing a first

5   complementary deoxyribonucleic acid (cDNA); (b) providing a second complementary
deoxyribonucleic acid (cDNA); (c) linking the first cDNA so produced to a first linker
sequence thereby forming a first linked nucleic acid, in which the first linker sequence
comprises a first recognition site for a first nucleic acid cleavage enzyme, preferably a first
restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first

10   recognition site; (d) linking the second cDNA so produced to a second linker sequence
thereby forming a second linked nucleic acid, in which the second linker sequence
comprises a second recognition site for a second nucleic acid cleavage enzyme, preferably
a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from
the second recognition site; (e) cleaving the first linked nucleic acid with the first nucleic

15   acid cleavage enzyme to provide a first linked tag, in which the first linked tag comprises a
first nucleotide sequence tag representative of a terminal transcribed sequence of the first
cDNA. (f) cleaving the second linked nucleic acid with the second nucleic acid cleavage
enzyme to provide a second linked tag, in which the second linked tag comprises a second
nucleotide sequence tag representative of a terminal transcribed sequence of the second

20   cDNA. (g) ligating the first and second tags to form a ditag; and (h) determining the
nucleotide sequence of at least one tag of the ditag to detect gene expression.

We provide, according to a fifteenth aspect of the present invention, a method of
sequentially generating subsequences from a nucleic acid sequence, the method
comprising the steps of: (a) providing a first nucleic acid sequence; (b) linking the first

25   nucleic acid sequence to an second nucleic acid sequence to form a linked nucleic acid, in
which the second nucleic acid sequence comprises a recognition site for a nucleic acid
cleavage enzyme that allows cleavage of the first nucleic acid sequence at a site distant
from the recognition site; and (c) cleaving the linked nucleic acid with the nucleic acid
cleavage enzyme to provide: (i) a third nucleic acid sequence comprising the second

nucleic acid linked to a subsequence of the first nucleic acid sequence, which subsequence comprises a 5' portion of the first nucleic acid sequence; and (ii) a fourth nucleic acid sequence comprising a 3' remainder portion of the first nucleic acid sequence; (d) repeating steps (a) to (c) at least once, in which the first nucleic acid sequence of step (a) is

5   provided by the fourth nucleic acid sequence of step (c)(ii); and (e) detecting the presence, identity or sequence of at least one third nucleic acid sequence or a 5' portion of a first nucleic acid sequence comprised therein.

We provide, according to a sixteenth aspect of the present invention, a method of obtaining a nucleotide sequence tag from a terminus of a nucleic acid, the method

10   comprising the steps of: (a) providing a first nucleic acid sequence; (b) linking the first nucleic acid sequence to an linker sequence to form a linked nucleic acid, in which the linker sequence comprises: (i) a first recognition site for a first nucleic acid cleavage enzyme that allows cleavage of the first nucleic acid sequence at a site distant from the first recognition site, and (ii) a second recognition site for a second nucleic acid cleavage

15·   enzyme that allows nucleic acid cleavage at a site distant from the second recognition site, said cleavage site located at a position within or about the first recognition site; in which the linked nucleic acid has the structure: 5' - second recognition site - first recognition site - first nucleic acid - 3' (c) cleaving the linked nucleic acid with the first nucleic acid cleavage enzyme to provide: (i) a linked tag comprising the linker sequence linked to a

20   nucleotide sequence tag representative of the first nucleic acid sequence and comprising a terminal portion thereof; and (ii) a second nucleic acid sequence comprising a remainder portion of the first nucleic acid;

Preferably, the first nucleic acid comprises a complementary deoxyribonucleic acid (cDNA) having a terminus comprising a 5' terminal transcribed sequence of a gene, and in

25   which the linker sequence is linked to said terminus.

Preferably, the first nucleic acid comprises a complementary deoxyribonucleic acid (cDNA) having a terminus comprising a 3' terminal transcribed sequence of a gene, and in which the linker sequence is linked to said terminus.

14

Preferably, the second nucleic acid cleavage enzyme comprises a restriction endonuclease, preferably a Type IIS restriction endonuclease, whose recognition site is 6 bases or greater, preferably MmeI.

Preferably, the first nucleic acid cleavage enzyme comprises a restriction
5   endonuclease, preferably a Type IIS restriction endonuclease, preferably BseRI.

There is provided, according to a seventeenth aspect of the present invention, method of sequentially generating a plurality of nucleic acid sequences each comprising a nucleotide sequence tag from a nucleic acid, the method comprising repeating steps (a) to (c) of any of the sixteenth aspects of the invention at least once, in which the first nucleic
10   acid sequence of step (a) is provided by the second nucleic acid sequence of step (c)(ii).

According to a eighteenth aspect of the present invention, we provide a method of providing an indication of an instance of expression of a gene, the method comprising a method according to any preceding aspect of the invention, and further comprising the step of detecting the presence, sequence or identity of the linked tag or the nucleotide sequence
15   tag to provide an indication of an instance of gene expression.

We provide, according to a nineteenth aspect of the invention, a method of detecting gene expression, the method comprising the steps of: (a) providing a first linked tag and a second linked tag, each independently produced by a method according to any preceding aspect of the invention; (b) linking the first linked tag and the second linked tag
20   such that the nucleotide sequence tag portion of one linked tag is linked to the nucleotide sequence tag of the other linked tag to form a ditag, the ditag comprising terminal transcribed sequences from first and second genes; and (c) detecting the presence or identity of the ditag, or at least one nucleotide sequence tag comprised therein, to detect gene expression.

25   Preferably, each of the first and second linker sequences comprised in the first and second linked tags comprises an amplification primer sequence, and in which the method

15

further comprises a step of amplifying the ditag, preferably by means of the polymerase chain reaction (PCR).

Preferably, the method further comprises the steps of: (d) cleaving the ditag with the or each second nucleic acid cleavage enzyme; (e) linking a plurality of the resultant trimmed ditags to form a concatamer; and (f) obtaining the nucleic acid sequence of at least a portion of the concatamer.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows an overview of a known SAGE technique. Immobilized cDNA fragments at 3'end on magnetic beads are digested by a 4-bp restriction enzyme NlaIII. On average, NlaIII cleaves along cDNA in every 250 base pairs. Linkers with a recognition site for BsmFI, a Type IIS type restriction enzyme, are ligated to the NlaIII cleaved end of cDNA fragments on the bead. BsmFI cuts the DNA asymmetrically [GTCCCN(14/10)] resulting in the release of a 14 base pair tag representing the corresponding transcript. The extracted tags are then ligated into ditags for PCR amplification followed by removing the linker arms with NlaIII digestion. Ditags with 4-bp anchor sequence are concatenated, cloned, and sequenced. **Figure 1B** is a schematic diagram of SAGE tag concatenate library construction.

Figure 2 is a schematic diagram of the 5'and 3'Terminal SAGE techniques described in this document and its application in genome annotation. 5'and 3'Terminal SAGE tags from full-length transcripts in a transcriptome are extracted using IIS type restriction enzymes. Tags are concatenated, cloned, sequenced, counted, and mapped to chromosome. Mapping of 5' and 3'tags to genome sequences allows precise localization and identification of genes as well as gene activities on chromosomes. Overlapping tags generated by serial rounds of SAGE Walking will immensely increase the tag specificity and confidence for identification of new gene and confirmation of predicted genes. The 5' tags also allow quick identification of large number of promoter sequences.

Figure 3 is a schematic diagram showing the 5'Terminal SAGE and SAGE Walking techniques described in this document. See Detailed Description for details.

Figure 4 is a schematic diagram showing the 3'Terminal SAGE and SAGE Walking techniques described in this document. See Detailed Description for details.

5   SEQUENCE LISTING

Appendix A shows the sequences of the various linkers and primers used in the methods and compositions described here, in particular in the Examples. The sequences shown are:

NotI-dT15 primer used for cDNA synthesis; Biotin-NotI linker; MmeI-BseRI
10   Linker A (48nt); MmeI-BseRI Linker B (48nt); second round MmeI-BseRI Linker A (50nt); second round MmeI-BseRI Linker B (50nt); PCR primer A (29nt, 20nt); PCR primer B (29nt, 20nt); FseI-dT15 primer (for cDNA synthesis).; 5' biotin linker (The biotin oligo is same as the PCR primer A); 1/2FseI-MmeI linker (to introduce MmeI site and remove polyA); Second round MmeI-BseRI Linker A (50nt); Second round MmeI-
15   BseRI Linker B (50nt); PCR primer A (29nt, 20nt); PCR primer B (29nt, 20nt).; NotI-dT20 primer; NotI Linker top; NotI Linker bottom; Linker A top (N5); Linker A top (N6); Linker A bottom; Linker B top (N5); Linker B top (N6); Linker B bottomx; PCR primer A; PCR primer B; GsuI-dT16 primer; MmeI-BseRI Linker A top; MmeI-BseRI Linker A bottom; MmeI-BseRI Linker B top; MmeI-BseRI Linker B bottom; SalI adaptor top; SalI
20   adaptor bottom; PCR primer A; PCR primer B.The methods and compositions described here may suitably employ any one or more of the sequences shown in the Sequence Listing.

DETAILED DESCRIPTION

The methods and compositions described here enable the isolation of defined
25   nucleotide sequence tags from termini of nucleic acids. We provide methods for the

detection of gene expression in a particular cell or tissue, or cell extract, for example, including at a particular developmental stage or in a particular disease state. Nucleotide sequence tags derived from cDNA can provide information on the gene, allele, or isoform which is expressed, and their incidence in a sample reflects the level of expression of the

5   gene. Our methods therefore enable quantitative and qualitative analysis of gene expression.

In particular, our methods are useful for isolating nucleotide sequence tags which reflect the 5' and / or 3' sequences of transcripts corresponding to expressed genes. Such nucleotide sequence tags are therefore representative of a terminal transcribed sequence of

10   a gene. In general, they comprise a terminal transcribed sequence of a gene.

Such tags are referred to for convenience as "Terminal Tags", and the techniques for obtaining such terminal tags will be referred to, again for convenience only, as "Terminal SAGE".

As explained above, the prior art SAGE and LongSAGE techniques have

15   disadvantages associated with the fact that the tags produced using these techniques are essentially "internal" in origin (i.e., they correspond to internal sequences of the expressed genes).This is because, in the prior art SAGE techniques, the "start" of the tag is defined by the 5' most (or 3' most) terminal Tagging Enzyme site on the gene, while its "end" position is defined by the offset between the Tagging Enzyme recognition site and its

20   cutting site. While either the 5' end or the 3' end of the cDNA can be anchored in the known SAGE and LongSAGE techniques, this anchoring, and the fact that the cDNA is treated with the Anchoring Enzyme prior to ligation to the adaptors or linkers, means that the tags generated by the SAGE methods of the prior art essentially correspond to "internal" sequences.

25   Accordingly, pre-digestion of the cDNA with Anchoring Enzyme means that the position of the tags in relation to the entire sequence is essentially determined by the

position of the most terminal Anchoring Enzyme site in the transcribed sequence. The prior art SAGE methods therefore invariably result in "internal" nucleotide sequence tags.

In contrast, the Terminal SAGE techniques described in this document enable the isolation of nucleotide sequence tags which are "terminal" in origin. In other words, the
5   tags obtained using our techniques comprise the 5' or 3' sequences of the processed nucleic acids and hence the transcribed sequences of the expressed genes. For convenience, we refer to the method for obtaining a 5' terminal transcribed sequence of a gene described as "5' Terminal SAGE", and the method for obtaining a 3' terminal transcribed sequence of a gene "3' Terminal SAGE".

10   Similarly, the nucleotide sequence tag comprising a 5' terminal transcribed sequence of a gene may conveniently be referred to as a "5' terminal tag", and the nucleotide sequence tag comprising a 3' terminal transcribed sequence of a gene may be conveniently referred to as a "3' terminal tag". However, it will be appreciated that where a nucleic acid which is not part of a gene is being processed using the methods described
15   here, these terms may equally have more general meanings (i.e, as referring to the 5' terminal sequence or 3' terminal sequence, as the case may be, of the nucleic acid in question).

In the methods of Terminal SAGE as described here, a "first nucleic acid sequence" is first provided. This is lined with a "linker sequence" to form a "linked
20   nucleic acid". The linker sequence comprises a "first recognition site" for a "first nucleic acid cleavage enzyme". The first recognition site is such that that allows cleavage of the first nucleic acid sequence at a site distant from the first recognition site. The linker sequence also comprises a "second recognition site" for a "second nucleic acid cleavage enzyme", that allows nucleic acid cleavage at a site distant from the second recognition
25   site. The cleavage site for the second nucleic acid cleavage enzyme is located at a position within or about the first recognition site. The linked nucleic acid preferably has the structure: 5' - second recognition site - first recognition site - first nucleic acid - 3'

The linked nucleic acid is then cleaved with the first nucleic acid cleavage enzyme.
The products of this cleavage reaction include a linked tag comprising the linker sequence
linked to a <u>nucleotide sequence tag</u> representative of the first nucleic acid sequence and
comprising a terminal portion thereof; and a second nucleic acid sequence comprising a
5   remainder portion of the first nucleic acid.

In highly preferred embodiments, the methods described here involve anchoring an
entire full-length cDNA and ligating an adaptor/linker to the free end. The adaptor/linker
comprises a PCR primer site, as well as two Type IIS restriction enzyme recognition sites.
The first site may be referred to as the Tagging Enzyme site (here MmeI). In addition, a
10   site which may be referred to as the "Anchor Enzyme" site (e.g., BseRI) is also provided
for removal of the primer sequence following ligation and amplification of the ditags. The
amplified ditags are then concatamerised, sequenced, and analysed, as described in further
detail below.

It will be appreciated that where the first nucleic acid sequence comprises a cDNA,
15   the nucleotide sequence tag which is produced from the method comprises a terminal
transcribed sequence of the relevant gene. Preferably, the cDNA is first processed to
remove at least a portion of the 5' untranslated region (UTR) or the 3' UTR as the case
may be. Thus, for example, where a tag comprising a 3' terminal transcribed sequence is
desired, the cDNA may be processed to remove at least a portion of the polyA/T tail.
20   However, it will be appreciated that removal of the entirety of the 3' UTR such as the
polyA/T tail is not strictly necessary, provided the tag is long enough to capture sequence
information upstream of the polyA/T tail.

The nucleotide sequence tag which is produced may be detected to determine the
identity of the first nucleic acid. Its sequence may also be determined for this. In preferred
25   embodiments, the nucleotide sequence tag which is produced is linked "tail to tail" with
another nucleotide sequence tag to produce a "ditag", which is then analysed (for details
see below). The ditag may be amplified, for example, by PCR, by introducing appropriate
sequences in the linker sequence. Two or more ditags may be joined together to form

concatermers, and the sequence of the concatamers determined for high throughput
genomic screening.

"Nucleotide Sequence Tags"

The terms "tag" and "nucleotide sequence tag" as used in this document should be
5   taken as synonymous with each other, and to mean a short nucleotide sequence which is
diagnostic of a longer one. By this, we mean that the presence of the larger sequence may
be detected by detecting the presence of the tag. Preferably, identification of the tag
sequence, or at least a part of it, is sufficient to identify the longer sequence. In highly
preferred embodiments, the sequence of the nucleotide sequence tag uniquely identifies a
10   gene.

The tag sequence is typically derived from the longer sequence, and may be a
fragment of it. Preferably, the length of the tag is less than 15%, preferably less than 10%,
most preferably less than 5% or less of the length of the gene. The tag may be of any
length, but typically, the length of the tag is between 5-40 bases, preferably between 10-30
15   bases, more preferably between 15-20 bases in length.

Although longer sequence tags are preferred, the methods and compositions
described here may suitably be used with shorter tags, for example, tags of 5, 6, 7, 8, 9, 10,
11, 12, 13, 14 or 15 bases. However, preferably, the tags have a minimum length of 16
bases, and are preferably 17 bases, 18 bases, 19 bases, or preferably 20 bases or more.

20   In preferred embodiments, where the nucleotide sequence tag is of a gene, the
length of the tag (i.e., the amount of sequence derived from the longer sequence) is
sufficient to provide at least a preliminary indication of the identity of the gene. Preferably,
the length of the tag is sufficient to provide a unique indication of the identity of a gene,
i.e., it is long enough to identify the gene.

25   As will be apparent from the description below, the length of the tag may be varied
by choice of the first nucleic acid cleavage enzyme (i.e., the first Type IIS restriction

endonuclease in preferred embodiments), in particular, the "offset" by which the first
nucleic acid cleavage enzyme cuts from its recognition sequence.

Preferably, the tag is diagnostic of a gene, or a transcription or translation product
thereof. The gene, etc corresponding to the tag may be easily identified by hybridisation or

5   library screening, or by database comparison. The nucleotide sequence tag may be indicate
the presence of a gene in a cell (or organ, tissue or individual) or the expression of the
gene. Where a gene is highly expressed gene by a cell, the number of copies of the
nucleotide sequence tag corresponding to the gene would be expected to be higher than for
a gene whose expression is relatively low. Therefore, the number of copies of the

10   nucleotide sequence tag in any particular sample may be determined to establish the degree
or amount of expression of a gene. The sequence of the tag may be derived from a portion
of the sequence of the gene, which may be from a non-coding portion of the gene (e.g., an
intron, an untranslated region such as a 5' UTR or a 3' UTR) or a coding portion (e.g., an
exon), or a combination of the two (e.g., a junction). The sequence of the tag may

15   correspond to a sequence of the coding strand of the gene or mRNA or cDNA, or its
complement or opposite strand.

The nucleotide sequence tag may be derived from any part of the longer sequence.
Where the longer sequence comprises a gene, the nucleotide sequence tag in preferred
embodiments comprises a terminal transcribed sequence (the meaning of this term is

20   explained below). In highly preferred embodiments, the nucleotide sequence tag is derived
from a 5' terminal sequence, preferably a 5' terminal transcribed sequence. Alternatively,
or in addition, the nucleotide sequence tag is derived from a 3' terminal sequence,
preferably a 3' terminal transcribed sequence.

The nucleotide sequence tag may indicate the presence of an expression product of

25   a gene, such as a messenger RNA. The presence or identity of the tag may be determined
to establish whether a protein product is present in a cell, etc. Thus, where the "longer
sequence" comprises a gene, the nucleotide sequence tag may be used for establishing or
quantitating gene expression.

It will be appreciated that the gene which corresponds toe the nucleotide sequence tag may be one which is known to be expressed, whether in the particular cell, tissue or organism, or known to be expressed in general in other types of cells, tissues or organisms. Alternatively, it may be a completely unknown or new gene, or a new transcript

5   corresponding to a known gene, whether previously known to be expressed in the particular cell, etc or not.

Our methods may therefore be used to provide sequence "signatures" corresponding to terminal portions of nucleic acids, as opposed to internal portions. Such terminal sequence information, including terminal transcribed sequence information, is

10   useful for various purposes, as described in detail below.

"Terminal Portion"

By "terminal portion", we mean the sequence of a nucleic acid at or about the 5' or 3' terminus of the nucleic acid. The "terminal portion" may comprise any number of bases. It may comprise the extreme terminal base, or it may comprise sequence just within the

15   terminus (i.e., lacking the extreme terminal base). The "terminal portion" may lack 1, 2, 3, 4 or 5 bases of the extreme terminus. However, in preferred embodiments the terminal portion includes residues at the extreme terminus of the nucleic acid. Thus, in such preferred embodiments, the "terminal portion" comprises, preferably consists of, the first N residues, or the last N residues, of the nucleic acid, where N = 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,

20   11, 12, 13, 14, 15...29, 30, 31, 32, 33, 34 or 35 or more. In preferred embodiments, terminal portions include the extreme end, i.e., the extreme terminal base, the first or last nucleotide, residue, base or base pair in the particular nucleic acid sequence.

In relation to a coding sequence such as a gene or mRNA, the terminal portion or "terminal transcribed sequence" (and the terms "5' terminal transcribed sequence" and "3'

25   terminal transcribed sequence") should be understood to be defined in relation to the sequence of the gene as expressed in mRNA.

That is to say, the terminal transcribed sequence should preferably include sequences at the beginning or end, as the case may be, of the transcribed portion of a relevant nucleic acid sequence (i.e., a gene, an mRNA, a cDNA or a genomic sequence). A 5' terminal transcribed sequence will therefore typically comprise a portion corresponding to the 5' untranslated region (5' UTR) of a transcript. Similarly, a 3' terminal transcribed sequence will therefore typically comprise a portion corresponding to the 3' untranslated region (3' UTR) of a transcript. Preferably, however, at least a portion of the polyA/T tail is removed from the cDNA prior to it being processed, preferably the entirety of the polyA/T tail is removed from the cDNA. Where this occurs, the 3' terminal transcribed sequence will correspond to the 3' sequence of the mRNA as it is transcribed, before addition of the polyA/T tail.

A full length cDNA comprises four sections: 5' untranslated region, coding sequences (the sequences which translated into protein), 3' untranslated region and poly A tail. Poly A sequences do not exist in the genomic DNA but are added after the mRNA was processed to remove introns. So, by removing the poly A region from the cDNA and obtaining the terminal region of 3' end, it is possible using our techniques to identify the exact 3' border of the transcripts and map back to the corresponding chromosomes.

It will be appreciated that the cDNA may be further manipulated before being processed in the Terminal SAGE methods described here. For example, one or more residues may be removed from the relevant terminus. This embodiment may be useful to remove untranslated sequences, so that the nucleotide sequence tag comprises fewer residues of untranslated sequence. The untranslated sequence may be removed entirely from the relevant terminus, to leave only coding sequence (so that the nucleotide sequence tags generated correspond to 5' or 3' terminal coding sequences).

Accordingly, the "terminal transcribed sequence" preferably includes at least an extreme upstream portion, or at least an extreme downstream portion, of the sequence of an mRNA, cDNA, etc, as the case may be. However, as with the terminal portions discussed above, the "terminal transcribed sequence" may comprise the extreme terminal

24

base, or it may comprise sequence just within that base (i.e., lacking the extreme terminal base). The "terminal transcribed sequence" may lack 1, 2, 3, 4 or 5 bases of the extreme terminal base. In preferred embodiments, however, the "terminal transcribed sequence" includes the first base, or the last base, as the case may be.

5   In such preferred embodiments, the 5' terminal transcribed sequence includes the first 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides or bases of the transcribed portion of the gene. The 3' terminal transcribed sequence may include such numbers of nucleotides or bases of the transcribed portion of the gene, preferably not counting the polyA/T tail. In highly preferred
10   embodiments, the terminal transcribed sequence includes sequence corresponding to at least the first or last 16 bases, preferably at least the first or last 20 bases of the transcript.

However, as noted above, the 5' terminal transcribed sequences (for example, a 5' terminal transcribed sequence of a cDNA) may comprise a sequence corresponding to a location at or about the 5' terminus of the transcribed portion, but it preferably includes the
15   first base in the transcript. Similarly, a 3' terminal transcribed sequence, for example of a cDNA, may comprise a sequence corresponding to a location at or about the 3' terminus of the transcribed portion, but it preferably includes the last base, i.e., the last base which was transcribed from the gene.

It is apparent from the above that using our methods it is possible to determine the
20   identities of genes which are expressed by a particular cell type, tissue, organ or individual. This enables a gene expression profile to be compiled for the relevant cell, etc. Transcriptome analysis may also be readily carried out using our methods.

Our methods therefore enable both 5' and 3' terminal transcribed sequences to be obtained with ease.   ·

25   Furthermore, is will be apparent that the presence of a particular nucleotide sequence tag as a product of the reactions indicates an instance of expression of the

25

corresponding gene. Therefore, the level of expression of a particular gene by a particular cell, tissue, organ or individual may be established. It is also possible to determine which genes are expressed, and which genes are not expressed, in such cells, etc. Relative levels of gene expression may be compared between genes, and between cells, etc. It will be

5   apparent that our methods may also be used to determine differences in gene expression between different states of a cell, for example, a healthy state and a diseased state. Comparison of gene expression profiles of a cell (or tissue, etc) known to be diseased and a candidate cell may be used to diagnose particular diseases, or susceptibility to such diseases. Differences in gene expression profiles between different developmental states of

10   a cell, between pluripotent and differentiated cells, or between cells in different parts of the cell cycle may also be determined with ease.

Knowledge of 5' and/or 3' terminal sequences of a nucleic acid such as a gene provides many advantages, which have been mentioned in passing, and will be explained in greater detail below.

15   Other uses of the methods and compositions described here will be apparent to the skilled reader.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA or immunology, which are within the capabilities of a person of ordinary skill in the

20   art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press (this reference is informally known as "Maniatis"); Ausubel, F. M. et al. (1995 and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.);

25   B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential Techniques*, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, *In Situ Hybridization: Principles and Practice*; Oxford University Press; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; and, D. M. J. Lilley and

J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA* Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

TERMINAL SAGE

5   In a general aspect, the methods and compositions described here enable the production of a nucleotide sequence tag, or a number of nucleotide sequence tags, from the terminus of a nucleic acid such as a transcribed gene. In particular, our methods are useful for isolating nucleotide sequence tags which reflect the 5' and / or 3' termini of the transcribed sequences of expressed genes.

10   Our methods generally involve providing a first nucleic acid sequence of interest. Our methods are suitable for use on any nucleic acid sequence, but are most useful for DNA sequences, such as complementary deoxyribonucleic acid (cDNA) sequences. Use of cDNA sequences, typically generated for example by reverse transcription from an mRNA extracted from a cell, or derived from a library, is preferred for the gene expression aspects

15   of the methods and compositions described here.

In such embodiments, the cDNA preferably comprises a terminal transcribed sequence of the relevant gene, that is, either a 5' terminal transcribed sequence, or a 3' terminal transcribed sequence, or both. A number of methods are known for obtaining such cDNA, and are also disclosed in detail below. Where a tag with 5' sequence is

20   desired, "full length" cDNA with 5' terminal transcribed sequence may be provided. To obtain a tag with 3' terminal transcribed sequence, techniques may be employed to remove at least some or all of the polyT tail or optionally some non-coding sequence; alternatively, the length of the tag may be chosen so that it is long enough to span the polyA/T tail and capture at least some 3' terminal transcribed sequence of the cDNA in the tag.

27

Generation of Linked Nucleic Acids

The first nucleic acid is then linked to a linker sequence without any prior
processing, in particular without any prior cleavage step. Accordingly, in contrast to the
prior art methods, the first nucleic acid sequence (in preferred embodiments, a cDNA) is

5   not digested by restriction endonucleases prior to linking to the linker sequence. Thus, in
our Terminal SAGE methods no pre-digestion with a 4-base cutter (i.e., NlaIII) is carried
out before ligation to the adaptor. It is this difference that enables our Terminal SAGE
technique to generate sequence tags corresponding to the extreme ends of the DNA,
instead of internal sequence tags.

10   In preferred embodiments of the methods described here, therefore, the cDNA may
be attached to the linker as soon as it is made, so long as the terminal transcribed portions
are present in the cDNA. This enables sequence information from terminal transcribed
portions of the gene or cDNA to be present in the nucleotide sequence tags which are
produced by our methods.

15   The linker sequence is linked to the 5' terminus or the 3' terminus of the first
nucleic acid, depending on whether sequence information is to be obtained from the 5' or
3' end. Thus, in preferred embodiments where it is desired to obtain 5' terminal
transcribed sequence from a cDNA (i.e., in the method we refer to as "5' Terminal
SAGE"), the linker is linked to the 5' terminus of the cDNA. Likewise, to obtain nucleic

20   acid sequence information from the 3' terminal transcribed sequence of a cDNA in
preferred embodiments ("3' Terminal SAGE"), the linker is linked to the 3' terminus of
the cDNA.

Linkage of the first nucleic acid to the linker sequence produces a construct we
refer to as a "linked nucleic acid".

25   The linkage of the first nucleic acid to the linker sequence to produce the linked
nucleic acid may be by any means, but is preferably by ligation (for example, by use of
ligases). The first nucleic acid may be immobilised during linkage, for example, on a

28

microbead. Immobilisation eases the purification of products, but is not strictly necessary. Where immobilisation is carried out, the first nucleic acid is immobilised at the terminus which is not being linked. That is to say, if it is desired to obtain a nucleotide sequence tag from one end of the nucleic acid, the nucleic acid may be immobilised on a bead at the

5   other end. For example, the 5' cap of a transcript (the cDNA) can also be utilized for labeling or binding a capture means for isolation of a nucleotide sequence tag corresponding to the 3' terminal transcribed sequence.

The first nucleic acid may be provided with a capture means for this purpose. The capture means may comprise a binding element, as known in the art, such as biotin,

10   strepavidin, digoxigenin, etc. Any suitable binding element or capture means may be employed. The microbead may be magnetic.

Linker Sequences

The linker sequence at least comprises a first recognition site for a first nucleic acid cleavage enzyme. The first nucleic acid cleavage enzyme is such that it is capable of

15   cleaving nucleic acid at a site remote and preferably downstream from its recognition sequence. For example, where 5' sequence information is desired from a cDNA sequence, the cleavage site of the first nucleic acid cleavage enzyme is preferably 3' of the recognition sequence, relative to the coding strand of the cDNA.

Linker sequences may be constructed using means known in the art, for example,

20   known oligonucleotide synthesis techniques.

The location of the first recognition site for the first nucleic acid is such that the cleavage site is preferably present in the first nucleic acid sequence. For example, the cleavage site may be located in the sequence of the cDNA which is linked to the linker sequence. Such an arrangement enables the capture of some or more sequence information

25   from the cDNA by cleavage of the nucleic acid by the first nucleic acid cleavage enzyme, as described later. Needless to say, the offset between the recognition site and the cleavage

29

site of the first nucleic acid cleavage enzyme may be manipulated to obtain more or less sequence information, again as described below.

The first nucleic acid cleavage enzyme preferably comprises a restriction enzyme or restriction endonuclease, preferably a Type IIS restriction endonuclease. However, the

5   use of artificial or modified enzymes is envisaged, as described in detail below. The first nucleic acid cleavage enzyme (such as a restriction endonuclease) may sometimes be referred to as a "Tagging Enzyme". The distance (i.e., the number of bases) between the recognition site of the nucleic acid cleavage enzyme and its cleavage site may be varied, but will typically be between 5 and 15 or more (for example 20, 25, 30 etc). The larger this

10   "offset", the more sequence information is captured in the tag (as will be explained below).

In highly preferred embodiments, the first nucleic acid cleavage enzyme comprises a restriction endonuclease, preferably a Type IIS restriction endonuclease, preferably BseRI.

15   The linker sequence may further comprise a second recognition site for a second nucleic acid cleavage enzyme. The second nucleic acid cleavage enzyme may sometimes be referred to as an "Anchoring Enzyme". The second recognition site enables the second nucleic acid cleavage enzyme to cleave at a site distant from the second recognition site. Such an embodiment is useful where high throughput analysis by means of ditags is

20   desired (see later). The second recognition site where present is located on the linker sequence such that the second nucleic acid cleavage enzyme cleavage site is at a position within or about the first recognition site. Preferably, the cleavage site of the second nucleic acid cleavage enzyme is located within the first recognition site.

Preferably, the second nucleic acid cleavage enzyme comprises a restriction

25   endonuclease, preferably a Type IIS restriction endonuclease, whose recognition site is 6 bases or greater, preferably MmeI. Preferably, the second nucleic acid cleavage enzyme is one which produces overhangs (i.e., is not a "blunt cutter").

In preferred embodiments, the linked nucleic acid comprising the first nucleic acid sequence and the linker sequence has the arrangement 5' - second recognition site - first recognition site - first nucleic acid - 3'. In such embodiments, therefore, the first recognition site is located between the first nucleic acid and the second recognition site.

5   *Generation of Linked Tags and Nucleotide Sequence Tags*

The linked nucleic acid is then subject to cleavage by the first restriction enzyme. This produces two products. The first product comprises the linker sequence linked to a terminal portion of the first nucleic acid sequence, and may be referred to as a "linked tag". Such a terminal portion comprises the nucleotide sequence tag, and is representative
10   of the first nucleic acid sequence. Preferably, the first nucleic acid cleavage enzyme is one which generates an overhang, preferably a 3' overhang, and preferably therefore the nucleotide sequence tag comprises a 3' overhang at its 3' end.

The second product of the cleavage of the linked nucleic acid with the first nucleic acid cleavage enzyme comprises the remainder of the first nucleic acid, lacking the
15   terminal portion (see below for a use of this in generating further tags).

It will be apparent that detecting the nucleotide sequence tag enables the determination of the identity of the first nucleic acid sequence. Thus, in the preferred embodiment where the first nucleic acid sequence comprises a cDNA, the nucleotide sequence tag comprises a terminal transcribed portion of the cDNA, and hence is
20   representative of the terminal transcribed sequence of the expressed gene.

TAG ANALYSIS

The nucleotide sequence tags generated may be identified, and in addition may have their sequences determined.

Detection of the nucleotide sequence tag may be undertaken by any means, for
25   example, by hybridisation, pull down, gel analysis; fragment length analysis, antibody

31

binding, Single Strand Conformation Polymorphism (SSCP) analysis, mass spectrometry, MALDI, etc. Clonal analysis, as described in further detail below, may also be carried out. Quantitation of the amount of sequence tag may be done by any means known in the art, for example, hybridisation using a suitably labelled probe and quantitation of signal

5   emitted by bound probe. Radioactive and non-radioactive methods are envisaged for this.

For example, the tags may be used to screen an appropriate library to obtain further sequence information. The tag itself may be used as a probe, or a oligonucleotide probe produced which comprises or corresponds to the tag sequence. The probe is used to screen for example a cDNA library, and a cDNA clone obtained. The cDNA may be sequenced

10   and compared to databases to determine its identity.

The term "oligonucleotide" as used herein refers to primers or oligomer fragments comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide.

15   In preferred embodiments, however, the nucleotide sequence tag is detected or quantitated, preferably both, by determining its sequence. This may be achieved by isolating the various nucleotide sequence tags obtained by the procedure, cloning or subcloning them into suitable vectors, and sequencing the cloned tags.

As noted above, the nucleotide sequence tags resulting from a reaction may be

20   analysed or sequenced individually.

For example, clonal sequencing may be carried out to identify the tags produced. Clonal sequencing is similar to limiting dilution techniques used in the cloning of cell lines, and involves dilution of linked tags, ditags or concatamers thereof, and placement into individual receptacles, such that each receptacle contains about one DNA molecule

25   per receptacle. The DNA in each receptacle may then be amplified and sequenced by standard methods known in the art, including mass spectroscopy.

32

We provide an oligonucleotide composition having at least two defined nucleotide sequence tags, wherein at least one of the sequence tags corresponds to at least one expressed gene, and in which at least one of the nucleotide sequence tags is generated by a Terminal SAGE method as described here. The composition may comprise about 1 to 200

5   ditags, and preferably about 8 to 20 ditags. Such compositions are useful for the analysis of gene expression by identifying the defined nucleotide sequence tag corresponding to an expressed gene in a cell, tissue or cell extract, for example.

Ditag Analysis

However, in addition to, or as an alternative to, such individual analysis, the tags

10   may be combined or linked into multimeric structures, and the multimeric structures themselves analysed to determine the identity and/or quantity of the component tags, and hence the expressed genes in preferred embodiments.

By the term "multimeric", we intend to include anything that comprises more than one monomer. Hence, multimeric includes dimers, trimers, tetramers, etc.

15   We therefore provide a method of detecting gene expression, the method comprising the steps of: (a) providing a first linked tag and a second linked tag, each independently produced by a Terminal SAGE method as described; (b) linking the first linked tag and the second linked tag such that the nucleotide sequence tag portion of one linked tag is linked to the nucleotide sequence tag of the other linked tag to form a ditag,

20   the ditag comprising terminal sequences from first and second genes; and (c) detecting the presence or identity of the ditag, or at least one nucleotide sequence tag comprised therein, to detect gene expression.

Thus, in such preferred embodiments, the tags which result from the methods as described above are dimerised to form ditags. By "ditag", we mean a nucleic acid sequence

25   which comprises two linked tags joined in any fashion. The ditag may comprise only sequences from the relevant genes, or it may further include one or more linker sequences, preferably at the ends.

Each ditag therefore represents two defined nucleotide sequences of at least one transcript, representative of at least one gene. Typically, a ditag represents two transcripts from two distinct genes. The presence of a defined nucleotide sequence tag within the ditag is indicative of expression of a gene having a sequence of that tag. As described

5   below, ditags may be amplified before analysis. However, the analysis of ditags, formed prior to any amplification step, provides a means to eliminate potential distortions introduced by amplification, e.g., PCR.

The pairing of tags for the formation of ditags is a random event. The number of different tags is expected to be large, therefore, the probability of any two tags being

10   coupled in the same ditag is small, even for abundant transcripts. Therefore, repeated ditags potentially produced by biased standard amplification and/or cloning methods are readily excluded from analysis.

The dimerisation of the tags into ditags is preferably done in a "tail to tail" fashion, with the portion of the nucleotide sequence tag furthest from the linker sequence being

15   referred to as the "tail". That is to say, two linked tags are linked to each other via their nucleotide sequence tag portions. The "linker" portions are therefore at the termini of the ditags, with the two nucleotide sequence tags in the middle sandwiched therebetween. Accordingly, the ditag preferably has a structure 5' - linker sequence (I) - nucleotide sequence tag (I) - nucleotide sequence tag (II) - linker sequence (II) - 3'.

20   Cleavage of the linked nucleic acid may give rise to blunt ends or overhanging ends - e.g., 5' or 3' overhangs. In the latter case, the two linked tags are conveniently linked via their overhangs (see Figure 3 for an example of such linking by overhangs). Overhangs enable efficient linkage or ligation. Linkage via blunt ends is also possible, where the cleavage reaction produces such blunt ends. Preferential linkage at such blunt

25   ends may be achieved by using linkers which are dephosphorylated at their 5' ends. Of course, it will be appreciated that overhanging ends may be "polished", or made blunt, if needed. This may be achieved by exposing the nucleic acid to any suitable enzyme which removes the overhangs, such as an enzyme comprising the appropriate exonuclease

34

activity. Thus, an enzyme comprising 3'-5' exonuclease activity may be used to remove 3'
overhangs, and an enzyme comprising 5'-3' exonuclease activity may be used to remove
5' overhangs. For example, the 3'-5' exonuclease activity of Klenow fragment may be
used to generate blunt ends from a 3' overhang (as described in Maniatis).

5   However, it will be appreciated that conversion from overhangs to blunt ends
results in loss of sequence information. For example, where 20 base tags are produced
with 2 base overhangs, ligation or linkage of such tags will produce 38 base ditags
comprising 20 bases of useful information in each tag. In contrast, removal of the
overhangs will result in the loss of information (2 bases) at the 3' end of each tag.

10   Linkage of the two linked tags may be by any means, but is preferably through
DNA or RNA ligases. Such ligases, for example, T4 RNA ligase and T4 DNA ligase, are
known in the art.

           The ditags once generated may be detected by hybridisation, etc, or sequenced
directly. Alternatively, and preferably, a number of ditags are linked to each other to form
15   concatamers, and the concatamers sequenced. Such an embodiment is suitable for high
throughput analysis of gene expression.

           Ditag Amplification

           The ditags may be amplified prior to their being detected, sequenced or
concatermerised. Amplification of the ditags increases their number, and hence increases
20   the sensitivity of the detection or sequencing of the tags or ditags.

           Amplification may be by any means, but is preferably by means of the polymerase
chain reaction (PCR). Polymerase chain reaction technologies are described in detail in
Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring
Harbor Press, Plainview NY) and U.S. Pat. No. 4,683,195.

The ditag can be amplified by utilizing primers which specifically hybridize to one strand of each linker. For this purpose, the linker sequence may comprise a suitable amplification primer sequence.

5   The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of primer extension product which is complementary to a nucleic acid strand is induced, i.e., in the presence of nucleotides and an agent for polymerization such as DNA polymerase and at a suitable temperature and pH. The primer is preferably single stranded for maximum efficiency in
10   amplification. Preferably, the primer is an oligodeoxy ribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including temperature and source of primer.

The primers herein are selected to be "substantially" complementary to the
15   different strands of each specific sequence to be amplified. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. Preferably, the primers are substantially complementary to at least part of the linker sequences.

The amplification primer sequences in the two linked tags may be the same, or
20   different. In preferred embodiments, therefore, the linked tags are generated by the methods described previously, and ligated to form ditags using DNA ligase, for example as shown in Figure 3 or 4. Appropriate PCR primer sequences, dNTPs, polymerase, etc, and a suitable reaction buffer are then added to the ditags, and the mixture subjected to rounds of amplification as known in the art. Alternatively, the ditags can be amplified by
25   cloning in prokaryotic-compatible vectors or by other amplification methods known to those of skill in the art.

Ditag Concatamerisation

As noted above, the ditags may be formed into higher order structures for processing and analysis. For example, concatamers or polymers of the ditags may be formed. Thus, in preferred embodiments, the identity of the nucleotide sequence tag is

5 determined by producing and concatamerising ditags. This allows large scale nucleotide sequence tag analysis to be carried out.

In preferred embodiments, all, or most, of the ditags arising from a reaction are concatermerised. In such an embodiment, the concatamer may be sequenced to determine the sequence of the component tags and ditags, without the necessity of sequencing the

10 tags and ditags individually. The ditags may be linked using ligase, in the same manner as for the ditags.

Appropriate "spacer" sequences may be introduced or incorporated into the concatamer to separate units of sequence which define the individual nucleotide sequence tags from which the concatamers are built up. The spacer sequences may be specifically

15 introduced in the concatamerisation reaction, by the use of appropriate linkers or adaptors, or they may be carried over from previous reactions. In the latter case, the spacer sequences may comprise the linker sequences, or portions thereof. For example, and as illustrated in Figures 3 and 5, the ditags which are formed may be ligated end to end to form concatamers; in such a situation, two nucleotide sequence tags are separated by two

20 linker sequences forming the spacer.

The concatamer may therefore have the structure 5' - linker sequence (I) - nucleotide sequence tag (I) - nucleotide sequence tag (II) - linker sequence (II) - linker sequence (III) - nucleotide sequence tag (IIII) - nucleotide sequence tag (IV) - linker sequence (IV) - etc - 3' or 5'-LNNL-LNNL-LNNL-LNNL-LNNL-LNNL-LNNL-LNNL-

25 LNNL-3', where L is a linker sequence, and N is a nucleotide sequence tag.

The presence of the "spacer" sequences enables the units comprising nucleotide sequence tags to be precisely defined. They may be ignored or stripped out during analysis of the sequence.

Alternatively, or in addition, the ditags may be treated or processed before being
5   linked to form concatamers. Such treatment may comprise stripping or removing at least a portion of the linker sequence from the ditags. In preferred embodiments, the treatment comprises removing the bulk or the majority of the linker sequence from the ditag.

In preferred embodiments, the linker sequence comprises a second recognition site for a second nucleic acid cleavage enzyme as described above, and the linked tag or ditag
10   is treated with the second nucleic acid cleavage enzyme, preferably BseRI. As explained above, the second recognition site is such that it directs nucleic acid cleavage by the second nucleic acid cleavage enzyme at a site remote from the recognition site. The separation between the first recognition site and the second recognition site is such that the second recognition site directs the second nucleic acid cleavage enzyme to cleave the
15   linked tag at or about the first recognition site (see Figures 3 and 5 for illustrative examples).

In preferred embodiments, therefore, cleavage with the second nucleic acid cleavage enzyme removes all but 2-4 bases of the linker sequence from the ditag. Preferably, cleavage with the second nucleic acid cleavage enzyme produces a two base
20   overhang linked to one strand of the nucleotide sequence tag. Preferably, the remnant of the linker sequence comprises a 4 base sequence comprising a 5' overhang of two bases. Thus, preferably, treatment with the second nucleic acid cleavage enzyme results in a "trimmed" ditag comprising the structure:

$$\frac{\text{ACXXXXXXXXXXXXXXXXXXXXXXXZZZZZZZZZZZZZZZZZZZZZGTCG}}{\text{GCTGXXXXXXXXXXXXXXXXXXXXXXXZZZZZZZZZZZZZZZZZZZZZZCA}}$$

25   Where Xs and Ys represent sequences (the length of which may vary) from two nucleotide sequence tags.

38

In this preferred embodiment, the concatamer may be easily formed by joining the trimmed ditags by their CG/ GC overhangs. The concatamer may be isolated and cloned into a suitable vector for handling, propagation and sequencing.

The trimmed ditag preferably comprises between 12 to 120 base pairs, preferably
5   between 18 to 46 base pairs, preferably 40 base pairs.

Cloning and Sequencing

The linked tags, ditags, or concatamers once generated may be detected by hybridisation, etc, or sequenced directly. They may then be sequenced.

Among the standard procedures for cloning the nucleotide sequence tags is
10   insertion of the tags into vectors such as plasmids or phage. The linked tag, ditag or concatamers of ditags produced by the method may be cloned into recombinant vectors for further analysis, e.g., sequence analysis, plaque/plasmid hybridization using the tags as probes, by methods known to those of skill in the art.

The term "recombinant vector" refers to a plasmid, virus or other vehicle known in
15   the art that has been manipulated by insertion or incorporation of the linked tag, ditag or concatamer genetic sequences. Such vectors contain a promoter sequence which facilitates the efficient transcription of the a marker genetic sequence for example. The vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use include for
20   example, pBlueScript (Stratagene, La Jolla, Calif.); pBC, pSL301 (Invitrogen) and other similar vectors known to those of skill in the art. Preferably, the linked tags, ditags or concatamers thereof are ligated into a vector for sequencing purposes.

Vectors in which the linked tags, ditags or concatamers are cloned can be transferred into a suitable host cell. "Host cells" are cells in which a vector can be
25   propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there

39

may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.

5 Transformation of a host cell with a vector containing ditag(s) may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as E. Coli, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl.sub.2 method using procedures well known in the art. Alternatively, MgCl.sub.2 or RbCl can be used. Transformation can also be performed by electroporation or other

10 commonly used methods in the art.

The linked tags, ditags etc present in a particular clone can be sequenced by standard methods (see for example, Current Protocols in Molecular Biology, supra, Unit 7) either manually or using automated methods.

DATABASE COMPARISONS

15 One of the differences between the 5' and 3' Terminal SAGE methods described here, as compared to the prior art methods, is that the tags are extracted from the terminal 5' ends and 3' ends. In contrast, the prior art methods extract tags which are internal to the sequence; these tags are those that flank anchoring sites such as NlaIII or DpnII.

Accordingly, the methods described here are particularly useful for genome

20 analysis. Such genome analysis is advantageously undertaken through database comparisons. The generation of 5' terminal tags using the methods described here enable the generation of sequence information which represents the starting of genes or transcripts. Likewise, generation of 3' terminal tags provide sequence information representing the end point of genes or transcripts. Such terminal tags may be compared

25 against databases of known genes, expressed sequence tags, genomic databases, etc, to identify the nature of the gene which is expressed. With this direct mapping, expression

40

frequency of known genes located on genome sequences can be measured by the number
of appearances of the corresponding 5' and 3' tags. Thus, the higher the number of tags
corresponding to a particular gene is present, the higher its level of expression in the
particular sample.

5   Hence, in a preferred embodiment, database comparison is carried out by: making
the 5' and 3' tags pairs that most likely represent the staring points and end points of genes
or transcripts and mapping the tag pairs directly to genome sequences. In addition,
alternative transcription start sites and polyadenalytion sites can be identified and
quantified. Furthermore, previously uncharacterised genes on chromosomal sequences can
10   be readily identified and quantified by this direct mapping of tag pairs.

         The sequences of the tags, ditags, and/or concatamers obtained may be compared
with suitable sequence databases, such as GenBank, to determine their identity and/or
relationships. Furthermore, it will be appreciated that comparison may be made to
databases such as chromosomal DNA sequence databases and cDNA databases.

15   We therefore provide a method of identifying a first mRNA molecule or a first
cDNA molecule reverse transcribed from the first mRNA molecule with a known
sequence in a database, comprising the step of: matching a first nucleotide sequence which
is located at a defined position at the 5' or 3' terminus of a transcribed sequence within the
first mRNA or first cDNA molecule to a second nucleotide sequence in a database
20   consisting of mRNA and/or cDNA sequences which occur at the defined position in their
respective mRNA or cDNA molecules, whereby the first nucleotide sequence is identified
with the known sequence in the database.

         We also provide for a method of identifying a first mRNA molecule or a first
cDNA molecule reverse transcribed from the first mRNA molecule with a known
25   sequence in a database, comprising the step of: matching a first nucleotide sequence which
is located at a defined position in a first mRNA or first cDNA molecule, wherein the
defined position is at the 5' or 3 terminus of a transcribed sequence in the first mRNA or

first cDNA molecule, to a second nucleotide sequence in a database; determining that the second nucleotide sequence in the database is located at the defined position in its respective mRNA or cDNA molecule, whereby the first nucleotide sequence is identified with the known sequence in the database.

5   We further provide a method of identifying a cDNA molecule which is not represented in a database, comprising the steps of: comparing a first nucleotide sequence which has a predefined position at the 5' or 3' terminus of a transcribed sequence within a messenger RNA, or a cDNA molecule reverse transcribed from the messenger RNA to a database of nucleotide sequences; if no nucleotide sequences are found in the database

10   which both match the first nucleotide sequence and occur at the defined position in an mRNA or cDNA, then hybridizing an oligonucleotide comprising the first nucleotide sequence to a cDNA clone in a library; and determining that the first nucleotide sequence is located at the defined position in the cDNA clone, whereby the cDNA molecule is identified which was not present in the database.

15   It will be appreciated that it is not necessary to merely compare a single nucleotide sequence against the database, and that it is possible (and perhaps more efficient) to compare pairs of nucleotide sequences against the database. Such pairs preferably comprise a nucleotide sequence corresponding to the 5' terminus of a transcribed sequence (i.e., a "5' terminal tag"), and a nucleotide sequence corresponding to the 3' terminus of a

20   transcribed sequence (i.e., a "3' terminal tag"). In preferred embodiments, the pair comprises a 5' terminal tag and a 3' terminal tag of the same transcribed sequence (e.g., the same gene). Where there is uncertainty, the pair comprises terminal tags which are most likely to represent the ends of the relevant sequence. Thus, the pair in such preferred embodiments contains the information from the starting point and the ending point of a

25   gene, transcript, etc. The pair therefore is sufficient to represent a unit of transcription, a full-length mRNA, or a gene.

Comparison of such pairs against the database may confirm the presence of a known corresponding gene or cDNA having the corresponding termini within the

42

database, indicating that that known sequence within the database is expressed "in real life" in the sample (i.e., tissue, cell, etc) in question. However, it may be the case that a match is not found in the database; this would indicate that a sequence having the relevant termini was not previously known to have existed or be expressed. Such sequences may

5   represent new genes, or previously unknown transcripts of known genes (having for example different transcription starting sites or different polyadenalytion sites, or both).

Identification of such unknown genes or novel transcripts will aid in genomic mapping and annotation. It will be appreciated that database comparisons using the nucleotide sequence tags generated by our methods, particularly in pairs as described

10   above, will (in cases of new genes or new transcripts) immediately provide boundary sequences of the particular new genes or transcripts, as their 5' termini and 3' termini will be known. Full-length cDNA sequences of the newly identified genes can be cloned by using conventional means. Full-length sequences of the new transcripts may similarly be isolated. It will be appreciated that primers designed from the tag sequences would enable

·15   the cloning of the full length sequence from PCR of a genomic or cDNA library or RT-PCR from mRNA.

We also provide a method to verify computationally predicted genes based on genome sequences, comprising the steps of: mapping the pair of 5' and 3' terminal tag sequences directly to the genome sequences; identifying the tag sequences that are mapped

20   to the predicted regions. The match of the tag sequences to the predicted gene sequences will provide evidence of the existence of the genes.

In general, the nucleotide sequence tags, linked tags, ditags and concatamers may be compared against sequence databases in the same manner as described in the prior art SAGE and LongSAGE techniques. Reference is therefore made to descriptions of these

25   techniques, in particular, US Patent Numbers 695,937, 5,866,330 and 6,383,743 as well sa WO 02/10438, hereby incorporated by reference. The following paragraphs in this section are adapted from US 6,383,743.

43

It is envisioned that the identification of differentially expressed genes using the

Terminal SAGE method as described here can be used in combination with other

genomics techniques. For example, individual nucleotide sequence tags or linked tags, and

preferably ditags, can be hybridized with oligonucleotides immobilized on a solid support

5   (e.g., nitrocellulose filter, glass slide, silicon chip). Such techniques include "parallel

sequence analysis" as described below.

Briefly, parallel sequence analysis is performed after ditag preparation, wherein the

oligonucleotide sequences to which the ditags are hybridized are preferably unlabeled and

the ditag is preferably detectably labeled. Alternatively, the oligonucleotide can be labeled

10   rather than the ditag. The ditags can be detectably labeled, for example, with a

radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent

compound, a metal chelator, or an enzyme. Those of ordinary skill in the art will know of

other suitable labels for binding to the ditag, or will be able to ascertain such, using routine

experimentation. For example, PCR can be performed with labeled (e.g., fluorescein

15   tagged) primers. Preferably, the ditag contains a fluorescent end label.

The labeled or unlabeled ditags are separated into single-stranded molecules which

are preferably serially diluted and added to a solid support (e.g., a silicon chip as described

by Fodor, et al., Science, 251:767, 1991) containing oligonucleotides representing, for

example, every possible permutation of a 10-mer (e.g., in each grid of a chip). The solid

20   support is then used to determine differential expression of the tags contained within that

support (e.g., on a grid on a chip) by hybridization of the oligonucleotides on the solid

support with tags produced from cells under different conditions (e.g., different stage of

development, growth of cells in the absence and presence of a growth factor, normal

versus transformed cells, comparison of different tissue expression, etc). In the case of

25   fluoresceinated end labeled ditags, analysis of fluorescence is indicative of hybridization to

a particular 10-mer. When the immobilized oligonucleotide is fluoresceinated for example,

a loss of fluorescence due to quenching (by the proximity of the hybridized ditag to the

labeled oligo) is observed and is analyzed for the pattern of gene expression.

44

The concept of deriving a defined tag from a sequence is useful in matching tags of samples to a sequence database. In the preferred embodiment, a computer method may be used to match a sample sequence with known sequences.

In one embodiment, a sequence tag for a sample is compared to corresponding
5   information in a sequence database to identify known sequences that match the sample sequence. One or more tags can be determined for each sequence in the sequence database as the N base pairs adjacent to each anchoring enzyme site within the sequence. However, in the preferred embodiment, only the first anchoring enzyme site from the 3' end is used to determine a tag. In the preferred embodiment, the adjacent base pairs defining a tag are
10   on the 3' side of the anchoring enzyme site, and N is preferably 9.

A linear search through such a database may be used. However, in the preferred embodiment, a sequence tag from a sample is converted to a unique numeric representation by converting each base pair (A, C, G, or T) of an N-base tag to a number or "tag code" (e.g., A=0, C=1, G=2, T=3, or any other suitable mapping). A tag is determined
15   for each sequence of a sequence database as described above, and the tag is converted to a tag code in a similar manner. In the preferred embodiment, a set of tag codes for a sequence database is stored in a pointer file. The tag code for a sample sequence is compared to the tag codes in the pointer file to determine the location in the sequence database of the sequence corresponding to the sample tag code. (Multiple corresponding
20   sequences may exist if the sequence database has redundancies).

Figure 6 of US 6,383,743 is a block diagram of a tag code database access system. A sequence database 10 (e.g., the Human Genome Sequence Database) is processed as described above, such that each sequence has a tag code determined and stored in a pointer file 12. A sample tag code X for a sample is determined as described above, and stored
25   within a memory location 14 of a computer. The sample tag code X is compared to the pointer file 12 for a matching sequence tag code. If a match is found, a pointer associated with the matching sequence tag code is used to access the corresponding sequence in the sequence database 10.

The pointer file 12 may be in any of several formats. In one format, each entry of the pointer file 12 comprises a tag code and a pointer to a corresponding record in the sequence database 12. The sample tag code X can be compared to sequence tag codes in a linear search. Alternatively, the sequence tag codes can be sorted and a binary search used.

5   As another alternative, the sequence tag codes can be structured in a hierarchical tree structure (e.g., a B-tree), or as a singly or doubly linked list, or in any other conveniently searchable data structure or format.

In the preferred embodiment, each entry of the pointer file 12 comprises only a pointer to a corresponding record in the sequence database 10. In building the pointer file

10   12, each sequence tag code is assigned to an entry position in the pointer file 12 corresponding to the value of the tag code. For example, if a sequence tag code was "1043", a pointer to the corresponding record in the sequence database 10 would be stored in entry #1043 of the pointer file 12. The value of a sample tag code X can be used to directly address the location in the pointer file 12 that corresponds to the sample tag code

15   X, and thus rapidly access the pointer stored in that location in order to address the sequence database 10.

Because only four values are needed to represent all possible base pairs, using binary coded decimal (BCD) numbers for tag codes in conjunction with the preferred pointer file 12 structure leads to a "sparse" pointer file 12 that wastes memory or storage

20   space. Accordingly, preferably each tag code is transformed to number base 4 (i.e., 2 bits per code digit), in known fashion, resulting in a compact pointer file 12 structure. For example, for tag sequence "AGCT", with $A=00._2$, $C=01._2$, $G=10._2$, $T=11._2$, the base four representation in binary would be "00011011".

In contrast, the BCD representation would be "00000000 00000001 00000010

25   00000011". Of course, it should be understood that other mappings of base pairs to codes would provide equivalent function.

The concept of deriving a defined tag from a sample sequence is also useful in comparing different samples for similarity. In the preferred embodiment, a computer method is used to match sequence tags from different samples. For example, in comparing materials having a large number of sequences (e.g., tissue), the frequency of occurrence of

5   the various tags in a first sample can be mapped out as tag codes stored in a distribution or histogram-type data structure. For example, a table structured similar to pointer file 12 in Figure 4 of US6,383,743 may be used where each entry comprises a frequency of occurrence valvc. Thereafter, the various tags in a second sample can be generated, converted to tag codes, and compared to the table by directly addressing table entries with

10   the tag code. A count can be kept of the number of matches found, as well as the location of the matches, for output in text or graphic form on an output device, and/or for storage in a data storage system for later use.

The tag comparison aspects may be implemented in hardware or software, or a combination of both. Preferably, these aspects are implemented in computer programs

15   executing on a programmable computer comprising a processor, a data storage system (including volatile and non-volatile memory and/or storage elements), at least one input device, and at least one output device. Data input through one or more input devices for temporary or permanent storage in the data storage system includes sequences, and may include previously generated tags and tag codes for known and/or unknown sequences.

20   Program code is applied to the input data to perform the functions described above and generate output information. The output information is applied to one or more output devices, in known fashion.

Each such computer program is preferably stored on a storage media or device (e.g., ROM or magnetic diskette) readable by a general or special purpose programmable

25   computer, for configuring and operating the computer when the storage media or device is read by the computer to perform the procedures described herein. The inventive system may also be considered to be implemented as a computer-readable storage medium, configured with a computer program, where the storage medium so configured causes a

47

computer to operate in a specific and predefined manner to perform the functions described herein.

SAGE WALKING

As in the prior art SAGE techniques, the method described above enables the
5   production of a single nucleotide sequence tag for each first nucleic acid. That is to say, in preferred embodiments, only a single "signature" is obtained from each cDNA. However, it is possible to provide a plurality of nucleotide sequence tags using further steps.

Accordingly, we provide a method of generating a plurality of nucleic acid sequences, each comprising a nucleic acid sequence tag from a nucleic acid. The further
10 nucleotide sequence tags are derived from sequences internal to the nucleotide sequence tag produced initially. The method may be repeated as many times as desired, to produce as many different nucleotide sequence tags as needed from a particular nucleic acid sequence.

The method of generating multiple nucleotide sequence tags makes use of the
15 second product of the cleavage of the linked nucleic acid with the first nucleic acid cleavage enzyme, i.e., a "second nucleic acid". It will be recalled that the second nucleic acid is derived from the first nucleic acid by cleavage to remove an initial nucleotide sequence tag. The second nucleic acid therefore comprises a sequence of the first nucleic acid 3' of the first nucleotide sequence tag.

20   In order to obtain a further nucleotide sequence tag from the nucleic acid, a linker sequence is attached to the second nucleic acid, and the resulting structure subjected to cleavage by the first nucleic acid cleavage enzyme to release a further nucleotide sequence tag. The linker sequence may comprise the same or similar structure as described previously. In short, the process of providing a further tag merely feeds the second nucleic
25 acid produced by cleavage into the first step of the process already described. It will be appreciated that each round of this process produces an additional nucleotide sequence tag,

48

and that as many rounds of this process may be carried out as necessary, to produce as many nucleotide sequence tags as necessary. Each further iteration of the method produces a further internal sequence tag, going deeper and deeper into the nucleic acid.

5   Accordingly, we provide a method of generating a plurality of nucleic acid sequences, comprising the Terminal SAGE method as described in this document, with one or more rounds of further steps (a) to (c) as set out in Claim 1.

An embodiment of technique of SAGE Walking is described below, without limitation, with reference to Figure 5.

5' TERMINAL SAGE

10   The Terminal SAGE technique has been described generally in the description above. The 5' Terminal SAGE technique described in general and in detail in this section enables the production of nucleotide sequence tags corresponding to the 5' terminal sequence of a relevant nucleic acid. In preferred embodiments, the method enables the production of a nucleotide sequence tag comprising sequence corresponding to a 5'
15   terminal transcribed sequence of a gene, mRNA or cDNA.

We therefore provide a method of providing an indication of an instance of expression of a gene, the method comprising the steps of: (a) providing a complementary deoxyribonucleic acid (cDNA) having a terminus preferably comprising a 5' terminal transcribed sequence of a gene; (b) linking the cDNA to an linker sequence thereby
20   forming a linked nucleic acid, in which the linker sequence comprises a first recognition site for a first nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site; and (c) cleaving the linked nucleic acid with the first nucleic acid cleavage enzyme to provide a linked tag, in which the linked tag comprises a nucleotide sequence tag representative of a
25   5' terminal transcribed sequence of the gene; and (d) detecting the presence or identity of

49

the linked tag or the nucleotide sequence tag to provide an indication of an instance of gene expression.

Preferably, the cDNA is linked to an linker sequence at its 5' end relative to the coding strand, i.e., 5'-linker sequence- cDNA -3', to form the linked nucleic acid.

5   Preferably, the first recognition site for the first nucleic acid cleavage enzyme, preferably a first restriction endonuclease, allows nucleic acid cleavage at a site 3' of the first recognition site, relative to the coding strand. Preferably, the nucleic acid cleavage site cleaves within the sequence of the cDNA.

In order to provide a first nucleic acid sequence which is a cDNA in preferred

10   embodiments for 5' Terminal SAGE, it is necessary to provide cDNA with 5' terminal transcribed portions. In general, any method which is capable of producing "full length" cDNA is suitable for this purpose. Size fractionation may be used to filter out smaller non-full length species.

For example, full length cDNA may be synthesised by the oligo-capping method

15   described in Maruyama and Sugano, Gene 138, 171-174, 1994, Suzuki et al., Gene 200, 149-156, 1997 using appropriate oligo-dT primers. The oligo capping method replaces the cap structure of a mRNA with an oligoribonucleotide (r-oligo) to label the 5' end of eukaryotic mRNAs. The cap is removed with tobacco acid pyrophosphatase (TAP) and r-oligos ligated to decapped mRNAs with T4 RNA ligase. This reaction is made cap-

20   specific by removing 5'-phosphates of non-capped RNAs with alkaline phosphatase prior to TAP treatment. Unlike the conventional methods that label the 5' end of cDNAs, this method specifically labels the capped end of the mRNAs with a synthetic r-oligo prior to first-strand cDNA synthesis. The 5' end of the mRNA is identified quite simply by reverse transcription-polymerase chain reaction (RT-PCR).

25   Although the oligo-capping method is preferred, a number of other methods of making or enriching full length cDNA with 5' sequences are known in the art, and any of these may be employed for the purposes described here.

50

A number of libraries of full length cDNA are known in the art, and these may be used as well in the methods and compositions described here. Full length cDNA libraries from various organisms and tissue types may be obtained commercially from a number of manufacturers, such as ResGen (Invitrogen, see

5   http://www.resgen.com/products/PFL.php3). Furthermore, a database of full length sequences may be found for example, at the Institute of Medical Science, University of Tokyo (http://cdna.ims.u-tokyo.ac.jp/)

In the following detailed description, which should not be taken as limiting, reference is made to Figure 3. Reference is also made to the detailed protocols set out in

10   Examples 1 and 2.

To add the MmeI linkers to the starting point of transcripts, we have to have cDNA fragments that are 5' intact. In order to do so, the established cap-trapper method may be employed for full-length cDNA selection to ensure most of the substance cDNA fragments have the intact 5' end. The cap-trapper method is described in detail in Genomics 37 327-

15   336., Biotechniques 32 (5): 984-985 and Biotechniques 30 (6): 1250-1254.

Other techniques to enable full length cDNA to be obtained are also suitable. For example, full length cDNA may be obtained by using eIF-4E cap-binding protein to identify and bind to the 5' mRNA cap (Mol. Cell. Biol. 15 : 3363-3371). Furthermore, methods based on RNA terminal tagging with RNA ligase may also be used (Methods

20   Enzymol. 65: 65-74).

As we make full-length cDNA, we use NotI-dT15VN primer to initiate the cDNA synthesis so introduce a NotI site at the end of the polyA/T tail. After full-length cDNA are selected, the 3' end will be digested by NotI followed by a ligation of the biotin-NotI linker, so the 3'end biotinylated cDNA are able immobilized on streptavidin coated

25   magnetic beads. Since NotI is an 8-bp cuter, the possibility of internal cDNA digestion is rare.

The immobilized cDNA population is then divided in half for the addition of MmeI-BseRI linker A and MmeI-BseRI linker B. These linkers contain the same sequence for MmeI and BseRI sites, but have different sequences for PCR priming sites. Here MmeI is a IIS type enzyme that cut DNA 20-bp down stream from its recognition site

5 (TCCGACN20/18). MmeI is used for releasing tags, called the "Tag Enzyme" (TE). BseRI is another IIS type enzyme that cut DNA 10-bp apart from its recognition site (GAGGAGN10/8). BseRI will be used for removing the PCR arms and leave a minimal anchor sequences with the tags, called the "Anchor Enzyme" (AE).

MmeI digestion releases linked tags comprising a unique sequence signature
10 corresponding to the 5' portion of the transcribed gene.

After MmeI digestion, the released tags from the two populations may be combined and ligated. Every two tags are joined together face to face (tail to tail) with two base pairs overlapping to form a ditag flanked with linkers at both ends. The ditags are subsequently purified and amplified by PCR with biotinylated primer A and B. Ditags with different
15 linkers will be more efficiently amplified in PCR reaction than the one with same linker sequences.

The next technical trick is how to remove the long arms from the amplified ditags, keep the anchor sequence minimal, and make the tags with cohesive ends and ligatable to each other. We place a BseRI site next to the MmeI site apart by 6 base pairs in the linker
20 sequences. That will allow BseRI cut into the MmeI site (GAGGAGNNNNNNTC CG AC) and create a CG-3' overhang. The probability of having a BseRI site within the 20-bp tag sequences of all transcripts is very rare ($P =$ 0.00488). After purification, the trimmed ditags are ligated to each other resulting concatenated ditags separated each other with an anchor sequence CGAC. Because each
25 20-bp tag has two base pairs overlapping in a ditag unit and a 4-bp anchor sequence per ditag in concatenated clones that means information of every 21 bp sequence in the concatenated clones contains one tag representing one transcript molecule. To tag one million transcript molecules, we only need to generate 21000 concatenated clones (1000

bp) for sequencing at both ends of the clones (42000 seq. reads) assuming an average 500 bp quality sequences per read.

3' TERMINAL SAGE

The 3' Terminal SAGE technique described in general and in detail in this section
5   enables the production of nucleotide sequence tags corresponding to the 5' terminal sequence of a relevant nucleic acid. In preferred embodiments, the method enables the production of a nucleotide sequence tag comprising sequence corresponding to a 3' transcribed sequence of a gene, mRNA or cDNA.

We therefore provide a method of providing an indication of an instance of
10   expression of a gene, the method comprising the steps of: (a) providing a complementary deoxyribonucleic acid (cDNA) having a terminus comprising a 3' terminal transcribed sequence of a gene; (b) linking the cDNA to an linker sequence thereby forming a linked nucleic acid, in which the linker sequence comprises a first recognition site for a first nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic
15   acid cleavage at a site distant from the first recognition site; and (c) cleaving the linked nucleic acid with the first nucleic acid cleavage enzyme to provide a linked tag, in which the linked tag comprises a nucleotide sequence tag representative of a 3' terminal transcribed sequence of the gene; and (d) detecting the presence or identity of the linked tag or the nucleotide sequence tag to provide an indication of an instance of gene
20   expression.

In order to provide a first nucleic acid sequence which is a cDNA in preferred embodiments for 3' Terminal SAGE, it is necessary to provide cDNA comprising a terminus with 3' terminal transcribed portions. Preferably, at least some of the polyA/T tail at the 3' terminus of the cDNA can be removed. However, it will be appreciated that it is
25   not strictly necessary to remove the whole of the poly A/T tail from the cDNA, provided that at least some sequence from the transcribed portion is captured in the nucleotide sequence tag. Any polyT sequence which may be in the nucleotide sequence tag may be

ignored for analysis. Provided the nucleotide sequence tag is long enough, it will capture some transcribed sequence from the cDNA sufficient to identify the relevant gene.

Where it is desired to remove at least some of the polyA/T portion, any method which is capable of producing a cDNA without (or substantially without) a poly dT tail
5   may suitably be employed for this purpose. Such techniques are discussed in detail in Shibata et al (2001), Removal of polyA tails from full-length cDNA libraries for high efficiency sequencing, Biotechniques, 31(5), 1042-1049, 2001. As noted above, it is not necessary for the entirety of the polyA/T tail to be removed, so long as the nucleotide sequence tag is long enough to contain useful sequence information. Thus, for example,
10   the Shibata technique may produce cDNA with an average polyA tail length of 4 or fewer, but this does not matter provided the nucleotide sequence tag is long enough to capture 3' transcribed sequence of the gene.

In a particularly preferred embodiment, however, all of the polyA/T tail removed from the cDNA. Thus, in such embodiments, a cDNA having a terminus comprising a 3'
15   terminal transcribed sequence of a gene may in particular be provided by the following steps: (i) deriving a cDNA from an mRNA by reverse transcription with an primer comprising a sequence 5'-NV(T)^{13}CCGGCCGG-3', in which N = A, C, G or T and V = A, C or G; (ii) producing a double stranded cDNA therefrom and digesting the double stranded cDNA with FseI to produce a cleaved cDNA comprising

20   $3' \dfrac{\text{GGCCGG}}{\text{CC}}$ overhang; (iii) linking the cleaved cDNA to a linker

comprising $\dfrac{\text{pTCGGA}}{\text{GGCCAGCCT}}$; and (iv) cleaving the resulting molecule with MmeI to

produce a cDNA lacking a polyA/T tail.

In the following detailed description of 3' Terminal SAGE, reference is made to Figure 4. This detailed description should not be taken as limiting. Reference is also made
25   to the detailed protocols set out in Examples 3 and 4.

54

To add the MmeI linkers to the 3'end of cDNA fragments, we have to first remove the polyA/T tails precisely at their starting point. In order to do so, we use the biotin-FseI-dT13VN primer to initiate cDNA synthesis. The two anchor nucleotides (V = A, C, G; and N = A, C, G, T) will guide the primer to anneal at the first 13 As in the polyA tail of

5   mRNA. Thus all cDNA fragments will have a 13-bp polyA/T tail followed by an FseI site and a biotin at the end. Double strand cDNA will be first immobilized on magnetic beads, and then digested by MmeI enzyme to clean up any possible internal MmeI sites in cDNA. After polishing the ends, cDNA fragments are released from the beads by FseI digestion and create a cohesive 3'end. FseI is an 8-bp cuter like NotI, so the internal FseI sites in

10   cDNA are rare. A 1/2FseI-MmeI linker is first ligated to the cohesive 3' end, and then a biotin linker is added to the 5'end of cDNA. After adding the biotin-linker, the cDNA fragments are once again immobilized on magnetic beads, but this time are by the 5'ends, and with an external MmeI site located 18 base pairs (6 residuals from the FseI site after digestion and ligation and a 13-polyA/T tail) apart from the 3' extremity. A MmeI

15   digestion will precisely remove the polyA/T tail and create a two base pair overhang 3'end.

The polyA/T-less cDNA is then divided by half into two populations, one half is to add the MmeI-BseRI linker A, and the other half is to add the MmeI-BseRI linker B. At this point, an external MmeI site is precisely introduced at the 3' termini of transcripts. All

20   steps in the rest of the procedure including releasing SAGE tags, ligating ditags, amplifying, and concatenating are all exactly the same as in the 5' Terminal SAGE procedure.

NUCLEIC ACID CLEAVAGE ENZYMES

The techniques described here generally utilise nucleic acid cleaving or nicking

25   enzymes, such as DNA cleavage enzymes, which recognise and cleave specific nucleic acid sequences. Such enzymes are preferably restriction enzymes (restriction endonucleases). As used in this document, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes which bind to a specific double-stranded

DNA sequence termed a recognition site or recognition nucleotide sequence, and cut double-stranded DNA at or near the specific recognition site.

Preferably, the nucleic acid cleavage enzymes cleave the nucleic acid at a position outside of the recognition sequence. The cleavage position is therefore "offset" from the
5 recognition position, and the enzymes may for convenience be referred to as "offset cleavage enzymes". In particular, use of "Type IIS restriction enzymes" (described in further detail below) are preferred.

As described elsewhere, a linker comprising a recognition sequence for such an offset cleavage enzyme is joined to a cDNA molecule as a first step in providing a tag.

10   Although the use of Type IIS restriction enzymes is preferred in the methods and compositions described here, it will be appreciated that derivitised or modified or engineered versions of such enzymes may equally be used, provided they have the properties of sequence recognition and nucleic acid cleavage (or nicking) at sites distant from the cognate recognition sequences. Thus, the methods and compositions described
15 here employ enzymes which cleave nucleic acids at offset positions. All that is required for the 5' and 3' Terminal SAGE techniques is that the linker comprise a recognition site for an enzyme that allows nucleic cleavage at a site in the nucleic acid distant from the recognition site for the enzyme. Engineering methods, for example those described in Kim YG, Shi Y, Berg JM, Chandrasegaran S. (1997) Gene 1997 Dec 5;203(1):43-9, Smith J,
20 Berg JM, Chandrasegaran S. (1999) Nucleic Acids Res 1999 Jan 15;27(2):674-81 and Kim YG, Smith J, Durgesha M, Chandrasegaran S. (1998) Biol Chem 1998 Apr-May;379(4-5):489-95, may be used to enhance the cleavage efficiency, modify the recognition sequence, or to increase, decrease, or otherwise modify the offset between the recognition site and the cleavage site. Zinc finger binding domains may be used for engineering
25 chimeric restriction enzymes, as described in Kim,Y.-G., Cha,J. and Chandrasegaran,S. (1996) *Proc. Natl Acad. Sci. USA*, 93, 1156-1160, Huang,B., Schaeffer,C.J., Li,Q. and Tsai,M.-D. (1996) *J. Prot. Chem.*, 15, 481-489 and Kim,Y.-G., Shi,Y., Berg,J.M. and Chandrasegaran,S. (1997) *Gene*, 203, 43-49.

56

In particular, we envisage the use of chimeric enzymes comprising sequence recognition domains and nucleic acid cleavage domains. The recognition domains and the nucleic acid cleavage domains may be linked and separated by a linker of variable length, to allow cleavage to occur remotely from the recognition sequence.

5   The recognition domains are capable of recognising and binding to specific nucleic acid sequences, and may comprise, for example, zinc finger domains designed according to the rules established in WO 98/53057, WO 98/53060, WO 98/53058, WO 98/53059. Methods of engineering, as well as rational and rule based design of zinc fingers, are also generally known in the art. The nucleic acid cleavage domains are capable of nicking or

10   cleaving single or double stranded nucleic acids, and may be derived from known or existing cleavage domains found, for example, in restriction nucleases, DNAses or RNAses. The recognition domain and the cleavage domain in the chimeric enzyme may be separated by a linker to allow cleavage remote from the recognition site. Such linkers may comprise structured or flexible linkers as known in the art, and described for example in

15   WO 00/44568, which is hereby incorporated by reference. The length of the linkers may be modified according to the offet desired, i.e., a longer linker will be predicated where a longer tag is required.

      Indeed, it may be possible to employ completely artificial enzymes not derived from restriction enzymes which have this property. Such derivitised, modified or

20   engineered restriction enzymes, as well as artificial enzymes, having these properties, should be understood to be encompassed for use in the methods and compositions described here.

TYPE IIS RESTRICTION ENZYMES

      Specifically, the methods and compositions described here employ restriction

25   enzymes which do not cleave within their recognition sites, but instead cleave at sequences of defined distance from their recognition sequence. Such restriction enzymes are typically referred to as "Type IIS" restriction enzymes.

57

Type IIS restriction endonucleases cleave at a defined distance up to 20 bp away from their asymmetric recognition sites (Szybalski, W., Gene, 40:169, 1985). Examples of type IIS restriction endonucleases include BsmFI and FokI. Other similar enzymes will be known to those of skill in the art (see, Current Protocols in Molecular Biology, supra).

5   Type IIS restrictions suitable for use in the methods and compositions described here are shown in **Table 2** below. Sequence representations in the table use the standard abbreviations (*Eur. J. Biochem.* 150: 1-5, 1985) to represent ambiguity. Recognition sequences are written from 5' to 3', only one strand being given. If the point of cleavage has been determined, the precise site is marked with ^. The character _ is sometimes used

10   to mark the cut site on the complementary strand. Accordingly, it can be seen that the choice of the specific Type IIS restriction endonuclease will determine the offset, and hence the length of the specific sequence tag generated by the methods and compositions described here. It will be apparent that that the longer the offset and hence the tag, the more specific the sequence tag generated will be.

15   In preferred embodiments, the restriction endonuclease used is MmeI, which has a recognition sequence of TCCRACNNNNNNNNNNNNNNNNNNNN_NN^, and cuts at a position 20/18 bases from its recognition sequence, resulting a 3' protruding overhang of 2 nucleotides (2nt). Accordingly, we envisage the use of a linker comprising a TCCRAC sequence, more preferably a TCCGAC sequence. Cleavage of such a linker joined at its 3'

20   end to a nucleic acid sequence, for example a full length cDNA, will produce a tag comprising 20 bases on one strand, and 18 bases on the other. The strand comprising 20 bases may be referred to as the "top" strand, while the strand comprising 18 bases may be referred to as the "bottom" strand.

Type IIS enzymes are of special interest in molecular biology. These enzymes

25   recognize asymmetric base sequences and cleave DNA at a specified position up to 20 base pairs outside of the recognition site. Blunting the ends of their digestion products, followed by ligation, does not destroy their recognition sites. This property is useful in several applications, including the generation of deletions of increasing length (Hasan, N.,

58

et al., A novel multistep method for generating precise unidirectional deletions using
BspMI, a class-IIS restriction enzyme, Gene, 50, 55-62, 1986) and mapping the sequence
specificity of DNA modification (Posfai, G. and Szybalski, W., A simple method for
locating methylated bases in DNA, as applied to detect asymmetric methylation by
5   M.FokIA, Gene, 69, 147-151, 1988) and PCR product cloning. Due to the asymmetric
nature of their recognition sequences, type IIS R-M systems comprise two methylases, one
for each strand, sometimes each methylating a different base (Bitinaite, J., et al., Alw26I,
Eco31I and Esp3I - type IIs methyltransferases modifying cytosine and adenine in
complementary strands of the target DNA, Nucleic Acids Res., 20, 4981-4985, 1992).

10   Exemplary Type IIS restriction enzymes are described in the restriction enzyme
database REBASE (Roberts RJ, Macelis D. (2001) REBASE--restriction enzymes and
methylases. Nucleic Acids Res. 2001 Jan 1;29(1):268-9 and Roberts,R.J. and Macelis,D.
(1999) *Nucleic Acids Res.*, 27, 312–313), which may be accessed at rebase.neb.com.

            REBASE is a comprehensive database of information about restriction enzymes
15   and related proteins. It contains published and unpublished references, recognition and
cleavage sites, isoschizomers, commercial availability, methylation sensitivity, crystal and
sequence data. DNA methyltransferases, homing endonucleases, nicking enzymes,
specificity subunits and control proteins are also included. Most recently, putative DNA
methyltransferases and restriction enzymes, as predicted from analysis of genomic
20   sequences, are also listed. The data is distributed via Email, ftp (ftp.neb.com), and the Web
(http://rebase.neb.com).

Enzymes	Recognition Sequence	Isoschizomers
AarI	CACCTGCNNNN^NNNN_	-
AceIII	CAGCTCNNNNNNN^NNNN_	-
AloI	_NNNNN^NNNNNNNGAACNNNNNNTCC NNNNNNN_NNNNN^	-
BaeI	_NNNNN^NNNNNNNNNNACNNNNGTAY CNNNNNNN_NNNNN^	-
Bbr7I	GAAGACNNNNNNN^NNNN_	-
BbvI	GCAGCNNNNNNNN^NNNN_	AlwXI BseKI BseXI Bsp423I Bst12I Bst71I BstV1I
BbvII	GAAGACNN^NNNN_	BbsI Bbv16II BpiI BpuAI Bsc91I BspBS31I BspIS4I BspTS514I

59

		BstBS32I BstTS5I BstV2I
BccI	CCATCNNNN^N_	-
Bce83I	CTTGAGNNNNNNNNNNNNNN_NN^	BpuEI
BceAI	ACGGCNNNNNNNNNNNN^NN_	-
BcefI	ACGGCNNNNNNNNNNNN^N_	-
BcgI	_NN^NNNNNNNNNNCGANNNNNNTGCN NNNNNNNN_NN^	-
BciVI	GTATCCNNNNN_N^	BfuI
BfiI	ACTGGGNNNN_N^	BmrI
BinI	GGATCNNNN^N_	AclWI AlwI BspPI BstH9I Bst31TI EacI
BplI	_NNNNN^NNNNNNNNGAGNNNNNCTCN NNNNNNN_NNNNN^	-
BsaXI	_NNN^NNNNNNNNNACNNNNNCTCCNN NNNNN_NNN^	-
BscAI	GCATCNNNN^NN_	Bst19I
BseMII	CTCAGNNNNNNNN_NN^	-
BseRI	GAGGAGNNNNNNNN_NN^	-
BsgI	GTGCAGNNNNNNNNNNNNNN_NN^	-
BsmI	GAATG_CN^	Asp26HI Asp27HI Asp35HI Asp36HI Asp40HI Asp50HI BsaMI BscCI Mva1269I PctI
BsmAI	GTCTCN^NNNN_	Alw26I BsoMAI
BsmFI	GGGACNNNNNNNNNN^NNNN_	BspLU11III BstOZ616I
Bsp24I	_NNNNN^NNNNNNNNGACNNNNNNTGG NNNNNNN_NNNNN^	-
BspCNI	CTCAGNNNNNNN_NN^	-
BspMI	ACCTGCNNNN^NNNN_	Acc36I BfuAI BveI
BsrI	ACTG_GN^	Bse1I BseNI BsrSI Bst11I Tsp1I
BsrDI	GCAATG_NN^	Bse3DI BseMI
BstF5I	GGATG_NN^	BseGI
BtsI	GCAGTG_NN^	-
CjeI	_NNNNNN^NNNNNNNNCCANNNNNNGT NNNNNNNNN_NNNNNN^	-
CjePI	_NNNNNN^NNNNNNNCCANNNNNNNTC NNNNNNNN_NNNNNN^	-
EciI	GGCGGANNNNNNNN_NN^	-
Eco31I	GGTCTCN^NNNN_	Bli736I BsaI Bso31I BspTNI EcoA4I EcoO44I
Eco57I	CTGAAGNNNNNNNNNNNNNN_NN^	AcuI BspKT5I
Eco57MI	CTGRAGNNNNNNNNNNNNNN_NN^	-
Esp3I	CGTCTCN^NNNN_	BsmBI BstGZ53I
FalI	_NNNNN^NNNNNNNNAAGNNNNCTTN NNNNNNN_NNNNN^	-
FauI	CCCGCNNNN^NN_	Bme585I BstFZ438I SmuI
FokI	GGATGNNNNNNNNN^NNNN_	BstPZ418I

GsuI	CTGGAGNNNNNNNNNNNNNN_NN^	BpmI
HaeIV	_NNNNNN^NNNNNNNGAYNNNNNRTCN NNNNNNNN_NNNNN^	-
HgaI	GACGCNNNNN^NNNNN_	-
Hin4I	_NNNNN^NNNNNNNNGAYNNNNNVTCN NNNNNNN_NNNNN^	-
HphI	GGTGANNNNNNN_N^	AsuHPI
HpyAV	CCTTCNNNNN_N^	-
Ksp632I	CTCTTCN^NNN_	Bco5I Bco116I BcoKI BseZI Bst6I Bsu6I Eam1104I EarI
MboII	GAAGANNNNNNN_N^	NcuI
MlyI	GAGTCNNNNN^	SchI
MmeI	TCCRACNNNNNNNNNNNNNNNNNNNN_NN^	-
MnlI	CCTCNNNNNN_N^	-
PleI	GAGTCNNNN^N_	PpsI
PpiI	_NNNNN^NNNNNNNGAACNNNNNCTCN NNNNNNN_NNNNN^	-
PsrI	_NNNNN^NNNNNNNGAACNNNNNNTAC NNNNNNN_NNNNN^	-
RleAI	CCCACANNNNNNNNN_NNN^	-
SapI	GCTCTTCN^NNN_	VpaK32I
SfaNI	GCATCNNNNN^NNNN_	BspST5I LweI PhaI
SspD5I	GGTGANNNNNNNNN^	-
Sth132I	CCCGNNNN^NNNN_	-
StsI	GGATGNNNNNNNNNN^NNNN_	-
TaqII	GACCGANNNNNNNNN_NN^, CACCCANNNNNNNNN_NN^	-
TspDTI	ATGAANNNNNNNNN_NN^	-
TspGWI	ACGGANNNNNNNNN_NN^	-
TspRI	_NNCASTGNN^	-
Tth111II	CAARCANNNNNNNNN_NN^	-

Table 2: Type II restriction enzymes cleaving outside their recognition sequences (Type IIS restriction enzymes).

The invention is described further, for the purpose of illustration only, in the following examples.

USES

Our methods have specific advantages over prior art techniques as they enable the generation of terminal transcribed sequences from cDNAs. Knowledge of such terminal transcribed sequences enables the discrimination between genes which are similar over their internal regions. In addition, the 5' and 3' terminal transcribed sequences may be used as "launch pads" for the identification of upstream or downstream (as the case may be) non-coding, untranscribed, untranslated or control regions. For example, the promoters or other control regions (such as enhancers) of a particular gene may be obtained easily once its 5' terminal transcribed sequence is known, by means of "walking" techniques, or by searching sequence databases.

Promoters may be identified by a number of methods. For example, it is known that eukaryotic gene promoters are usually locates upstream of the transcription starting site and possess a consensus sequence such as CAAT box or TATA box. The 5' Terminal SAGE method described here essentially identifies the 5' transcription start site; sequences upstream of the transcription start site may be obtained by chromosomal walking, or preferably by examining a genomic database using standard bioinformatics tools to search for promoter consensus regions based on the presence of consensus sequences. The identity of putative promoters may be confirmed by making constructs with suitable reporters and examining expression of reporter, by means well known in the art.

Furthermore, once the 5' and the 3' terminal transcribed sequences are determined, it is a simple matter to obtain a full length clone (a cDNA clone or a genomic clone) from an mRNA or cDNA or genomic library. Appropriate primers corresponding to these sequences may be synthesised and used as PCR primers in a polymerase chain reaction to amplify the full length clone.

Specific uses of the terminal tags produced according to the methods and compositions described here are described. I particular, we describe specific uses of the

62

methods described here for transcriptome characterisation, genome annotation, novel gene discoveries, and promoter identification.

It will be apparent that the terminal transcribed sequences derived from cDNAs may be used for many other purposes, and that the skilled person will be aware of such

5   uses. Accordingly, the following uses should not be taken to be limiting.

Transcriptome Analysis

Due to the current limitations, the original SAGE technique has not been applied broadly and deeply comparing to other competing technologies such as microarrays. Many SAGE experiments done in the prior art are simply not deep enough to be statistically

10   significant, particularly to rare transcripts. The Terminal SAGE techniques, on the other hand, may be used to collect a large number of tag pairs of 5'and 3' Terminal SAGE for various genomes such as human and zebrafish.

Transcriptome Analysis of Zebrafish and Other Organisms

The 5'and 3' Terminal SAGE methods may be used in conjunction with large scale

15   sequencing efforts, for example, zebrafish full-length cDNA cloning and sequencing from a mixed adult fish library and an embryonic library, to obtain a comprehensive picture of zebrafish transcriptomes at embryonic and adult stages. The combination of these two approaches has the potential to provide a comprehensive disclosure of zebrafish transcriptomes and large number of full-length transcript clones and sequences.

20   The experimental data will be invaluable for thorough annotation of the upcoming zebrafish genome sequences.

Using the Terminal SAGE techniques, and obtaining one million 5'and 3'tag-pairs from zebrafish, it will only be necessary to process fewer than 40,000 Terminal SAGE clones (i.e., clones of concatamers) with fewer than 70,000 sequence reads on the

25   assumption that each SAGE concatamer clone is about 2kp; each clone will be sequenced from both ends; and each sequence read will provide 800bp in average.

63

This approach may be readily applied to other organisms, such as mouse, humans, etc.

Human Stem Cell Transcriptomes

5   More importantly, the new Terminal SAGE methods may be applied to stem cell research projects.

A deep and comprehensive characterization of stem cell transcriptomes has never been done, though some limited attempts have been reported using the original SAGE techniques. However, the data for novel genes involved in stem cell constitution is not convincing.

10   Use of the Terminal SAGE methods as described here to collect large number of tags will allow for the first time a complete characterization of stem cell transcriptomes, and will make huge contribution to human genome annotation. Comparisons may be made between embryonic stem cells (ES cells) and a committed type of stem cell for deep 5'and 3' sequence analyses.

15   We believe that it is possible to obtain a near complete list of genes expressed and their activities in stem cells by generating one million tag-pairs of 5'and 3' Terminal SAGE for each of the ES cell and the other cell. Compared to microarray analysis, this new approach will have a much better chance to convincingly identify key genes that are differentially expressed at low levels between these cells.

20   Any new transcript identified by this method may be easily isolated in full-length by RT-PCR using the 5'and 3' tag information.

64

Large Scale Promoter Identification

Applying the 5' Terminal SAGE techniques to cells such as zebrafish and human stem cell will allow the identification of the vast majority of genes at their transcript initiation sites.

5   The experimental data will enable the identification and extraction of promoter sequences for all of the 5' Terminal SAGE identified genes, and establish a large promoter database for human and zebrafish. These large set of expression-based promoter databases will provide a solid knowledge base for mining promoter functions, training computational programs for promoter predictions, and extending our understanding of comprehensive

10   gene regulatory networking mechanisms.

EXAMPLES

Example 1. 5' Terminal SAGE Operational Protocol

1.1   Full length cDNA synthesis

NotI-oligo dT primers (14 μg) and 20 μg of polyA$^+$ RNA are ethanol precipitated

15   and resuspended into 10 μl of ddH$_2$O. Heat up at 65°C for 10 min and left at 42°C for 1 min.

In a separate tube, mix the following components: 5X first strand synthesis buffer 30 μl, 0.1M DTT 11 μl, 10mM dNTP 9 μl, saturated trehalose 15 μl, 4.9M sorbitol 50 μl and Superscript II reverse transcriptase 15 μl. Mix with RNA from above and incubate at

20   40°C for 4 min, 50°C for 2 min and 56°C for 60 min. 2 μl of proteinase K (20 mg/ml) is added and the reaction is incubated at 45°C for 15 min followed by phenol/chloroform extraction and ethanol precipitation.

The RNA/cDNA heter-duplex is resuspended into 44.5 μl of ddH$_2$O. 3 μl of 1.1 M NaOAc pH 4.5 and 2.5 μl of 100mM NaIO$_4$ are added to oxidize the diol structures of the

mRNA. The 50 μl reaction is incubated on ice in the dark for 45 min followed by adding

0.5 μl of 10% SDS, 11 μl of 5 M NaCl and 61 μl of isopropanol.

The precipitated RNA/DNA is biotinylated in 50 μl of ddH₂O by added the 5μL

1M NaOAc (pH6.1), 5μL 10% (w/v) SDS and 150μL 10mM long-arm biotin hydrazide.

5   Leave at RT/dark/O/N. Add: 5μL 5M NaCl, 75μL 1M RNase-free NaOAc (pH6.1), 750μL

100% EtOH or 200 μL of 100% Isopropanol . -80°C/30'+*. Centrifuge at

14krpm/4°C/30'. Wash pellet w/ 70% (v/v) EtOH/30%, DEPC-treated ddH₂0, centrifuge

at 14krpm/4°C/10'. Remove XS liquid, air-dry pellet. Resuspend pellet in 70μL DEPC-

ddH₂0, then add: 10μL 10x RNaseI buffer, 25 U RNaseI / ug of starting mRNA. 37°C/30'.

10   Add 2.5μL of 40mg/mL Yeast tRNA and ½ volume of 5M NaCl to stop the reaction.

While the biotinylated RNA-DNA heteroduplex is ppting, prepare the Streptavidin-

labelled Dynabeads:

Pipet 500μL of M-280 Streptavidin beads into an RNase-free Eppendorf tube.

Place on magnet, wait @ least 30", and remove sup. Resuspend beads in 500μL 1x binding

15   buffer (2M NaCl, 50 mM EDTA, pH 8.0). Place on magnet, wait @ least 30", and remove

sup. Repeat the 1x binding buffer wash for 3 times. Resuspend beads in 500μL 1x binding

buffer w/ 100μg of Yeast tRNA. 30'+/4°C/mix occasionally. Place on magnet, wait @

least 30", and remove sup. Wash with 1x binding buffer for 3 times. Resuspend in 100μL

1x binding buffer. Mix beads and DNA-RNA heteroduplex (Vₜ=200μL), binding at 2 M

20   NaCl. 30'/RT/rotating. Place on magnet, wait @ least 30", and remove sup. Wash 2x

w/400μL of 1x binding buffer. Place on magnet, wait @ least 30", and remove sup. Wash

w/400μL of 0.4%(w/v) SDS plus 50μg/mL Yeast tRNA. Place on magnet, wait @ least

30", and remove sup. Wash w/400μL of 1x wash buffer (10mM Tris-HCl pH7.5, 0.2mM

EDTA, 10mM NaCl & 20%(v/v) Glycerol, 40 μg/mL Yeast tRNA). Place on magnet, wait

25   @ least 30", and remove sup. Wash w/400μL of 50μg/mL Yeast tRNA. Place on magnet,

wait @ least 30", and remove sup.

66

Release the first strand cDNA by alkali hydrolysis of RNA. Add: 50μL 50mM NaOH and 5 mM EDTA (pH8.0) 10'/RT/rotating. Transfer the sup. to another tube containing 50μL 1M Tris-Cl (pH7.5). Repeat the lysis procedure for 2 more times. The final volume is 300 μL.

5   *1.2   Single Strand Linker A & B ligation*

Pecipitate the single strand first cDNA with glycogen and divide the cDNA into 2 tubes, A and B. Add the following reagents to the each corresponding tube on ice.

Contents	Tube A	Tube B
cDNA	5μL	5μL
Linker A (N5)	1.6μg	
Linker A (N6)	0.4μg	
Linker B (N5)	1.6μg	
Linker B (N6)		0.4μg
Soln II (Takara kit)	10μl	10μl
Soln I (Takara ligation kit)	20μl	20μl
Total volume	40μl	

16°C/o/n. and then 70°C 10' to inactivate the ligase. Increase the volume to 200μl and phenol/chloroform extraction. Sephacryl -300 to remove the excess linkers and

10   precipitate the cDNA with EtoH and glycogen.

Resuspend the pellet with 60μl of ddH$_2$0, add 8μl 10XExtaq buffer, 8μl 2.5mM dNTP 4μl ExTaq enzymes. 65°C 5'   68°C 30'   72°C 10'.

Precipitate the cDNA with EtoH and glycogen. Resuspended with ddH$_2$0.

1.3   Binding cDNA to Magnetic Beads

15   The double strand cDNAs are digested with NotI at 37°C for 1 hour in a volume of 50μl. The enzyme is then inactivated with proteinase K and extracted with phenol/chloroform and then ethanol precipitated.

67

The samples are mixed with 200 ng of NotI linker adaptor. Ligation is carried out in total volume of 10μl at 16°C for overnight followed by 70°C for 10' to inactivate enzyme. The excess adaptor is removed by Sephacryl -300.

Dynabeads M280 streptoavidin beads are used to bind the Biotinylated cDNA fragments according to the manufacturer's recommendation.

1.4   Digesting the cDNA with Tagging Enzyme MmeI

Place the two tubes (A and B) on magnetic stand, remove the supernatant (wash buffer from Dynabeads).

Add the following reagents to each tube.

ddH$_2$0	86μl
MmeI	2μl
10X buffer	10μl
(1 :10) SAM	2μl
Total volume	100μl. Incubate at 37°C for 1 hour with mixing.

Remove the supernatant which contains the tags. Phenol/chloroform and precipitate.

Optionally, a Klenow fill-in reaction may be carried out to produce blunt ends. If carried out, the pellet is resuspended and the following carried out.

Add the following components to each tube containing 10μl of sample from the above.

10X Klenow buffer	5μl
100XBSA	1μl
dNTP (10mM each)	2.5μl
ddH$_2$0	30.5μl
Klenow polymerase	1μl
Total volume	50μl

Mix well and incubate for 30' at 37°C.

Pool the ditags and phenol/chloroform followed by EtOH precipitation.

The Klenow fill in step is optional, and may result in less sequence information being obtained (see elsewhere in this document for a detailed discussion).

· 5   **Example 2. Ligating tags to create ditags**

Resuspend the precipitated pellet from the above in 1.5µl and add 1.5µl of the following reagents to form the ditags.

3mM Tris-HCl, pH 7.5	1.25µl
10X Ligation buffer	0.75µl
ddH$_2$0	0.75µl
T4 ligase	1µl

Incubate at 16°C for overnight.

2.1   PCR Amplifying and Gel Purifying the 138 bp Ditags

10   Set up 200 to 300 reactions as following (in 96 PCR plates).

10XBV buffer	5µl
DMSO	3µl
dNTPmix	7.5µl
PCR primer A (175ng/µl)	2µl
PCR primer B (175ng/µl)	2µl
ddH$_2$0	29µl
Platinum Taq enzyme	0.5µl
Template (1: 230 dilution)	1µl
Total volume	50µl

Cycling condition: 95°C 2' 1 cycle. 95°C 30", 55°C 1', 70°C 1'. 27 cycles. 70°C 5'.

Run a diagnostic 4% agarose gel to analyze the PCR product and purify the 138 bp ditags by 12% polyacrylamide gel electrophoresis.

2.2   Digesting the Ditags with Anchoring Enzyme BseRI and Purifying the 46 Bp Ditag

Digest the 138bp ditags with BseRI to yield 46bp ditag.

138bp ditags	42µl
10X NEB buffer II	15µl
BseRI	12µl
ddH$_2$0	81µl
Total volume	150µl

5   And incubate at 37°C for 2 to 3 hours. Phenol/chloroform and EtoH precipitate. Run a diagnostic 4% agarose gel to check the efficiency of the digestion and purify the 46 bp ditags by 12% polyacrylamide gel electrophoresis.

2.3   Ligating the 46 bp Ditag to Form Concatamers

10   Set up the ligation reaction using the gel purified ditag in a total volume of 10µl and incubate 16 C for 2 to 3 hours. Gel purify the concatamers from 8% polyacrylamide, select the DNA size range around 2kbp.

2.4   Cloning Concatamers into Vector

15   In a separate reaction, digest the plasmid vector with HhaI and ligate the purified concatamers into the linearized vector following standard molecular biology protocol. Transform the ligation into high efficiency competent cells.

The concatamers of 5' Terminal SAGE tags may then be sequenced using conventional means.

20   **Example 3. 3' Terminal SAGE Operational Protocol**

3.1   cDNA synthesis

GsuI-dT16 primers (1μg) and 5μg of polyA⁺ RNA are mixed in final volume of 7μl. Heat up at 70°C for 10 min and leave on ice.

Synthesize the cDNA according to the manufacturer's recommendation (Invitrogen superscript cDNA synthesis system) but using the Biotinylated SalI adaptor. The excess adaptor is removed by Sephacryl -300.

3.2   Binding cDNA to Magnetic Beads

Dynabeads M280 streptoavidin beads are used to bind the Biotinylated cDNA fragments according to the manufacturer's recommendation.

3.3   Digesting the cDNA with GsuI to Remove PolyA Tail

The double strand cDNA on beads are digested with GsuI at 30 °C for 1 hour. After the digestion is completed, inactivating the enzyme by washing the tube twice with buffer containing 1%SDS. Four more wash with wash buffer (5mM Tris-HCl pH 7.5, 0.5mM EDTA. 1mM NaCl and 200μg/μl BSA). The last wash use 1X ligation buffer.

3.4   Ligating MmeI-BseRI Adaptors to cDNA

Place the tube on magnetic stand to remove the supernatant (the ligation buffer). Add the following reagents to the beads on ice.

	Tube A	Tube B
cDNA beads	beads	beads
MmeI-BseRI adaptor A (20ng/μl)	1.5μl	
MmeI-BseRI adaptor B (20ng/μl)	1.5μl	
TE	14μl	14μl
10X ligation buffer	2μl	2μl

Heat the tubes for 2' at 50 °C and cool to room temp. for 15' and chill the samples

on ice. Add 2.5µl T4 DNA ligase and mix. Incubate at 16 °C for 2 hours. Mix occasionally.

Wash the tubes with wash buffer to remove the excess adaptors.

3.5   Cleaving with Tagging Enzyme MmeI

5   Place the two tubes (A and B) on magnetic stand, remove the supernatant (wash

buffer). Add the following reagents to each tube.

ddH₂0	86µl
MmeI	2µl
10X buffer	10µl
(1 :10) SAM	2µl
Total volume	100µl.

Incubate at 37°C for 1 hour with mixing. Remove the supernatant which contains

the tags. Phenol/chloroform and precipitate.

10   *Optionally*, a Klenow fill-in reaction may be carried out to produce blunt ends. If

carried out, the pellet is resuspended and the following carried out.

Add the following components to each tube containing 10µl of sample from the

above section.

10X Klenow buffer	5µl
100XBSA	1µl
dNTP (10mM each)	2.5µl
ddH₂0	30.5µl
Klenow polymerase	1µl
Total volume	50µl

15   Mix well and incubate for 30' at 37°C. Pool the ditags and phenol/chloroform

followed by EtOH precipitation.

The Klenow fill in step is optional, and may result in less sequence information

being obtained (see elsewhere in this document for a detailed discussion).

72

Example 4. Ligating Tags to Create Ditags

Resuspend the pellet from the above in 1.5μl water and add 1.5μl of the following

reagents to form the ditags.

3mM Tris-HCl, pH 7.5	1.25μl
10X Ligation buffer	0.75μl
ddH₂0	0.75μl
T4 ligase	1μl

Incubate at 16°C for overnight.

5   *4.1   PCR Amplifying and Gel Purifying the 138 Bp Ditags*

Set up 200 to 300 reactions as following (in 96 PCR plates).

10XBV buffer	5μl
DMSO	3μl
DNTPmix	7.5μl
PCR primer A (175ng/μl)	2μl
PCR primer B (175ng/μl)	2μl
ddH₂0	29μl
Platinum Taq enzyme	0.5μl
Template (1: 230 dilution)	1μl
Total volume	50μl

Cycling condition: 95°C 2' 1 cycle. 95°C 30", 55°C 1', 70°C 1'. 27 cycles. 70°C

5'.

10   Run a diagnostic 4% agarose gel to analyze the PCR product and purify the 138 bp

ditags by 12% polyacrylamide gel electrophoresis.

4.2   Digesting the Ditags with Anchoring Enzyme BseRIi and Purifying the 46
Bp Ditag

Digest the 138bp ditags with BseRI to yield 46 bp ditag.

138bp ditags	42μl
10X NEB buffer II	15μl
BseRI	12μl

Total volume	150µl

And incubate at 37°C for 2 to 3 hours. Phenol/chloroform and EtoH precipitate.
Run a diagnostic 4% agarose gel to check the efficiency of the digestion and purify the 46
bp ditags by 12% polyacrylamide gel electrophoresis.

5

4.3   Ligating the 46 Bp Ditag to Form Concatamers

Set up the ligation reaction using the gel purified ditag in a total volume of 10µl
and incubate 16 C for 2 to 3 hours. Gel purify the concatamers from 8% polyacrylamide,
select the DNA size range from 1 to 1.5kbp, or .

10

4.4   Cloning Concatamers Into Vector

In a separate reaction, digest the plasmid vector with HhaI and ligate the purified
concatamers into the linearized vector following standard molecular biology protocol.
Transform the ligation into high efficiency competent cells.

15   **Example 5. SAGE Walking Operational Protocol**

Even 20-bp tags may still seem to be not long enough to be specific for mapping on
chromosomes. Sequence variations in tags caused by sequencing errors or point mutations
can make the mapping to genome sequence ambiguous. Longer tags can certainly add
more confidence to include certain level of mismatches. However, the longest cleavage

20   distance of IIS enzyme is 20-bp by MmeI. To overcome this constraint, we can actually
walk along the transcript sequence by reintroducing the MmeI site to the same cDNA that
already released the first tag, and perform another round of SAGE tag extraction,
amplification, and concatenation. The second SAGE will have 2-bp overlap with the first
tags on the same transcripts. These tiled two tags of one transcript add up total 38-bp tag

25   information that will be sufficient to tolerate variations due to SNP on either transcript
sequence or on the chromosome sequence in genome sequence database, or simply
sequence errors. We can even add a third or further rounds of SAGE walk if necessary.

5' SAGE Walk Operational Protocol

Follow the 5' terminal tag protocol to step: **Digesting the cDNA with tagging enzyme MmeI.** After the digestion is completed, inactivate the enzyme by washing the tube twice with buffer containing 1%SDS. Four more washes with wash buffer (5mM Tris-HCl pH 7.5, 0.5mM EDTA. 1mM NaCl and 200µg/µl BSA). For the last wash use 1X ligation buffer.

Ligating MmeI-BseRI Adaptors to cDNA.

Place the tube on magnetic stand to remove the supernatant (the ligation buffer). Add the following reagents to the beads on ice.

Contents	Tube A	Tube B
cDNA beads	beads	beads
MmeI-BseRI adaptor A (20ng/µl)	1.5µl	
MmeI-BseRI adaptor B (20ng/µl)		1.5µl
TE	14µl	14µl
10X ligation buffer	2µl	2µl

Heat the tubes for 2' at 50 °C and cool to room temp. for 15' and chill the samples on ice. Add 2.5µl T4 DNA ligase and mix. Incubate at 16 °C for 2 hours. Mix occasionally. Wash the tubes with wash buffer to remove the excess adaptors.

Cleaving with Tagging Enzyme MmeI

Place the two tubes (A and B) on magnetic stand, remove the supernatant (wash buffer). Add the following reagents to each tube: ddH20 86µl, MmeI 2µl, 10X buffer10µl (1 :10) SAM2µl. Total volume 100µl. Incubate at 37°C for 1 hour with mixing.

Remove the supernatant which contains the tags. Phenol/chloroform and precipitate.

Ligating Tags to Create Ditags

Resuspend the pellet in 1.5µl, mix both A and B tubes and add 1.5µl of the
following reagents to form the ditags: 3mM Tris-HCl, pH 7.5 1.25µl, 10X Ligation buffer
0.75µl, ddH$_2$0 0.75µl, T4 ligase 1µl. Incubate at 16°C for overnight.

5   *PCR Amplifying and Gel Purifying the 138 Bp Ditags*

Set up 200 to 300 reactions as following (in 96 PCR plates):

10XBV buffer	5µl
DMSO	3µl
dNTPmix	7.5µl
PCR primer A (175ng/µl)	2µl
PCR primer B (175ng/µl)	2µl
ddH$_2$0	29µl
Platinum Taq enzyme	0.5µl
Template (1: 230 dilution)	1µl
Total volume	50µl

Cycling condition: 95°C 2' 1 cycle. 95°C 30", 55°C 1', 70°C 1'. 27 cycles. 70°C
5'. Run a diagnostic 4% agarose gel to analyze the PCR product and purify the 138 bp
10   ditags by 12% polyacrylamide gel electrophoresis.

Digesting the Ditags with Anchoring Enzyme Bseri and Purifying the 48 Bp Ditag

Digest the 138bp ditags with BseRI to yield 48bp ditag.

138bp ditags	42µl
10X NEB buffer II	15µl
BseRI	12µl
ddH$_2$0	81µl
Total volume	150µl

And incubate at 37°C for 2 to 3 hours. Phenol/chloroform and EtoH precipitate.
Run a diagnostic 4% agarose gel to check the efficiency of the digestion and purify the 48
15   bp ditags by 12% polyacrylamide gel electrophoresis. Ligate the 48 bp ditag to form
concatamers.

Ligating the 48 Bp Ditag to Form Concatamers

Set up the ligation reaction using the gel purified ditag in a total volume of 10µl and incubate 16 C for 2 to 3 hours. Gel purify the concatamers from 8% polyacrylamide, select the DNA size range from 1 to 1.5kbp.

5   *Cloning concatamers into Vector*

In a separate reaction, digest the plasmid vector with HhaI and ligate the purified concatamers into the linearized vector following standard molecular biology protocol. Transform the ligation into high efficiency competent cells.

To keep on walking into the 3' end of the cDNA, just take the beads from step:

10   **Cleavage the cDNA with tagging enzyme MmeI and repeat the whole process again.**

3' SAGE Walk Operational Protocol

Follow the 3' terminal tag protocol to step: **Cleaving with Tagging enzyme MmeI.**

After the digestion is completed, inactivate the enzyme by washing the tube twice

15   with buffer containing 1%SDS. Four more washes with wash buffer (5mM Tris-HCl pH 7.5, 0.5mM EDTA. 1mM NaCl and 200µg/µl BSA). For the last wash use 1X ligation buffer.

Ligating MmeI-BseRI Adaptors to cDNA

Place the tube on magnetic stand to remove the supernatant (the ligation buffer).

20   Add the following reagents to the beads on ice.

Contents	Tube A	Tube B
cDNA beads	beads	beads
MmeI-BseRI adaptor A (20ng/µl)	1.5µl	
MmeI-BseRI adaptor B (20ng/µl)		1.5µl
TE	14µl	14µl

10X ligation buffer	2μl	2μl

Heat the tubes for 2' at 50 °C and cool to room temp. for 15' and chill the samples on ice. Add 2.5μl T4 DNA ligase and mix. Incubate at 16 °C for 2 hours. Mix occasionally. Wash the tubes with wash buffer to remove the excess adaptors.

5   *Cleaving with Tagging enzyme MmeI*

Place the two tubes (A and B) on magnetic stand, remove the supernatant (wash buffer). Add the following reagents to each tube.

ddH₂0	86μl
MmeI	2μl
10X buffer	10μl
(1 :10) SAM	2μl
Total volume	100μl.

Incubate at 37°C for 1 hour with mixing. Remove the supernatant which contains the tags. Phenol/chloroform and precipitate. Resuspend the pellet.

10   *Ligating Tags to Create Ditags*

Pool the A and B tubes. Resuspend the pellet in 1.5μl and add 1.5μl of the following reagents to form the ditags.

3mM Tris-HCl, pH 7.5	1.25μl
10X Ligation buffer	0.75μl
ddH₂0	0.75μl
T4 ligase	1μl

Incubate at 16°C for overnight.

PCR Amplifying and Gel Purifying the 138 Bp Ditags

15   Set up 200 to 300 reactions as following (in 96 PCR plates).

10XBV buffer	5μl
DMSO	3μl
dNTPmix	7.5μl

PCR primer A (175ng/μl)	2μl
PCR primer B (175ng/μl)	2μl
ddH₂0	29μl
Platinum Taq enzyme	0.5μl
Template (1: 230 dilution)	1μl
Total volume	50μl

Cycling condition: 95°C 2' 1 cycle. 95°C 30", 55°C 1', 70°C 1'. 27 cycles.70°C 5'.

Run a diagnostic 4% agarose gel to analyze the PCR product and purify the 138 bp ditags

by 12% polyacrylamide gel electrophoresis.

Digesting the Ditags with Anchoring Enzyme Bseri and Purifying the 48 Bp Ditag

5   Digest the 138bp ditags with BseRI to yield 48bp ditag.

138bp ditags	42μl
10X NEB buffer II	15μl
BseRI	12μl
ddH₂0	81μl
Total volume	150μl

And incubate at 37°C for 2 to 3 hours. Phenol/chloroform and EtoH precipitate.

Run a diagnostic 4% agarose gel to check the efficiency of the digestion and purify the 48

bp ditags by 12% polyacrylamide gel electrophoresis.

Ligating the 48 Bp Ditag to Form Concatamers

10   Set up the ligation reaction using the gel purified ditag in a total volume of 10μl

and incubate 16 C for 2 to 3 hours. Gel purify the concatamers from 8% polyacrylamide,

select the DNA size range from 1 to 1.5kbp.

Cloning Concatamers Into Vector

In a separate reaction, digest the plasmid vector with HhaI and ligate the purified

15   concatamers into the linearized vector following standard molecular biology protocol.

Transform the ligation into high efficiency competent cells.

To keep on walking toward the 5' end of the cDNA, just take the beads from step: **Cleavage the cDNA with tagging enzyme MmeI** and repeat the whole process again.

Example 6. DNA Sequencing and Data Analysis

5   DNA templates of the concatamer clones are prepared and subject for standard sequencing analysis. A typical DNA sequence provides about 800bp nucleotide sequences and contains about 17-18 ditags, or 30-40 tags.

With a concatamer clone of larger than 2000bp of insert, sequencing analysis is performed from both ends to generate up to 80 tags per run. Therefore, a modest sequencing effort of 12,500 clones generates over one million tags, and 25,000 clones

10   sequences (50,000 reads) generates one million pairs of 5' and 3' LongSAGE tags.

After sequencing of generating the draw sequence data, the ditag sequences are first extracted then the single tags. Both 5' and 3' tags are compared together to the corresponding genome sequence database using BLAST. Pairs of 5' and 3' tags of known genes and putative genes are clustered based on genome and cDNA sequences.

15   REFERENCES

Each of the applications and patents mentioned in this document, and each document cited or referenced in each of the above applications and patents, including during the prosecution of each of the applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or

20   mentioned in each of the applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

80

Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed

5   should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the claims.

APPENDIX A: SEQUENCES

5' TERMINAL SAGE LINKERS AND PRIMERS

```
NotI-dT15 primer for cDNA synthesis
    5'-GACTAGTTCTAGATCGCGAGCGGCCGCCC(T)₁₅VN
                            NotI
```

```
Biotin-NotI linker
    5'-biotin-GACTAGTTCTAGATCGCGAGC
              CTGATCAAGATCTAGCGCTCGCCGGp-3
```

```
MmeI-BseRI Linker A (48nt)
                            BseRI          MmeI
5'-TTT GGA TTT GCT GGT GCA GTA CAA CTA GGC GAGGAGCGTCTCTCCGAC
    a-CCT AAA CGA CCA CGT CAT GTT GAT CCG CTCCTCGCAGAGAGGCTG-P
                                                BsmBI
```

```
MmeI-BseRI Linker B (48nt)
                            BseRI          MmeI
5'-TTT CTG CTC GAA TTC AAG CTT CTA ACG TAC GAGGAGCGTCTCTCCGAC
    a-GAC GAG CTT AAG TTC GAA GAT TGC ATG CTCCTCGCAGAGAGGCTG-P
                                                BsmBI
```

```
Second round MmeI-BseRI Linker A (50nt)
                            BseRI          MmeI
5'-TTT GGA TTT GCT GGT GCA GTA CAA CTA GGC GAGGAGCGTCTCTCCGACNN
    a-CCT AAA CGA CCA CGT CAT GTT GAT CCG CTCCTCGCAGAGAGGCTG-P
                                                BsmBI
```

```
Second round MmeI-BseRI Linker B (50nt)
                            BseRI          MmeI
5'-TTT CTG CTC GAA TTC AAG CTT CTA ACG TAC GAGGAGCGTCTCTCCGACNN
    a-GAC GAG CTT AAG TTC GAA GAT TGC ATG CTCCTCGCAGAGAGGCTG-P
                                                BsmBI
```

```
PCR primer A (29nt, 20nt)
    biotin-5'-GTG CTC GTG GGA TTT GCT GGT GCA GTA CA
```

```
PCR primer B (29nt, 20nt)
    biotin-5'-GAG CTC GTG CTG CTC GAA TTC AAG CTT CT
```

3' TERMINAL SAGE LINKERS AND PRIMERS

```
FseI-dT15 primer (for cDNA synthesis)
    biotin-GACTAGTTCTAGATCGCGAGGCCGGCC(T)₁₃VN
                                FseI
```

```
5' biotin linker
    (The biotin oligo is same as the PCR primer A)
    5'-biotin-GTGCTCGTGGGATTTGCTGGTGCAGTACA
```

82

CACGAGCACCCTAAAGCACCACGTCATGT-p-3'

1/2FseI-MmeI linker (to introduce MmeI site and remove polyA)

5   pTCGGATCGCGATCTAGAACTAGTC
          3'-GGCCAGCCTAGCGCTAGATCTTGATCAGTTT-5'
              MmeI

Second round MmeI-BseRI Linker A (50nt)

10   BseRI   MmeI
      5'-TTT GGA TTT GCT GGT GCA GTA CAA CTA GGC GAGGAGCGTCTCTCCGACNN
          a-CCT AAA CGA CCA CGT CAT GTT GAT CCG CTCCTCGCAGAGAGGCTG-P
                                                    BsmBI

15   Second round MmeI-BseRI Linker B (50nt)
                                            BseRI   MmeI
      5'-TTT CTG CTC GAA TTC AAG CTT CTA ACG TAC GAGGAGCGTCTCTCCGACNN
          a-GAC GAG CTT AAG TTC GAA GAT TGC ATG CTCCTCGCAGAGAGGCTG-P
                                                    BsmBI
20

      PCR primer A (29nt, 20nt)
            biotin-5'-GTG CTC GTG GGA TTT GCT GGT GCA GTA CA

      PCR primer B (29nt, 20nt)
25   biotin-5'-GAG CTC GTG CTG CTC GAA TTC AAG CTT CT

EXAMPLES 1 & 2 PRIMER / LINKER SEQUENCES

      NotI-dT20 primer   40 mers
      GAGAGAGAGAGCGGCCGCTTTTTTTTTTTTTTTTTTTTVN
30
      NotI Linker top   25 mers
      5'phosphate-GGCCGCTCGCGATCTAGAACTAGTC

      NotI Linker bottom   21mers
35   5'biotin-GACTAGTTCTAGATCGCGAGC

      Linker A top (N5)   54mers
      TTTGGATTTGCTGGTGCAGTACAACTAGGCGAGGAGCGTCTCTCCGACGNNNNN

40   Linker A top (N6)   54mers
      TTTGGATTTGCTGGTGCAGTACAACTAGGCGAGGAGCGTCTCTCCGACNNNNNN

      Linker A bottom   45mers
      5'phosphate-GTCGGAGAGACGCTCCTCGCCTAGTTGTACTGCACCAGCAAATCC
45
      Linker B top (N5)   54mers
      TTTCTGCTCGAATTCAAGCTTCTAACGTACGAGGAGCGTCTCTCCGACGNNNNN

      Linker B top (N6)   54mers
50   TTTCTGCTCGAATTCAAGCTTCTAACGTACGAGGAGCGTCTCTCCGACNNNNNN

      Linker B bottom   45mers

```
5'phosphate-GTCGGAGAGACGCTCCTCGTACGTTAGAAGCTTGAATTCGAGCAG


PCR primer A                        29mers
GTGCTCGTGGGATTTGCTGGTGCAGTACA


PCR primer B                        29mers
GAGCTCGTGCTGCTCGAATTCAAGCTTCT
```

EXAMPLES 3 & 4 PRIMER / LINKER SEQUENCES

```
GsuI-dT16 primer            34 mers
GAGAGAGAGACTGGAGTTTTTTTTTTTTTTTTVN


MmeI-BseRI Linker A top                   50 mers
5'-TTTGGATTTGCTGGTGCAGTACAACTAGGCGAGGAGCGTCTCTCCGACTT


MmeI-BseRI Linker A bottom                45 mers
5'phosphate-GTCGGAGAGACGCTCCTCGCCTAGTTGTACTGCACCAGCAAATCC


MmeI-BseRI Linker B top                   50 mers
5'-TTTCTGCTCGAATTCAAGCTTCTAACGTACGAGGAGCGTCTCTCCGACTT


MmeI-BseRI Linker B bottom                45mers
5'phosphate-GTCGGAGAGACGCTCCTCGTACGTTAGAAGCTTGAATTCGAGCAG


SalI adaptor top            16mers
5'biotin-TCGACCCACGCGTCCG


SalI adaptor bottom              16mers
5'phosphate-CGGACGCGTGGGTCGA


PCR primer A                        29mers
GTGCTCGTGGGATTTGCTGGTGCAGTACA


PCR primer B                        29mers
GAGCTCGTGCTGCTCGAATTCAAGCTTCT
```

EXAMPLE 5 SAGE WALKING PRIMER / LINKER SEQUENCES

5' SAGE Walking Primer / Linker sequences

```
Linker A top          50mers
TTTGGATTTGCTGGTGCAGTACAACTAGGCGAGGAGCGTCTCTCCGACNN


Linker A bottom         45mers
5'phosphate-GTCGGAGAGACGCTCCTCGCCTAGTTGTACTGCACCAGCAAATCC


Linker B top          50mers
TTTCTGCTCGAATTCAAGCTTCTAACGTACGAGGAGCGTCTCTCCGACNN


Linker B bottom         45mers
```

5'phosphate-GTCGGAGAGACGCTCCTCGTACGTTAGAAGCTTGAATTCGAGCAG
PCR primer A   29mers
GTGCTCGTGGGATTTGCTGGTGCAGTACA

5   PCR primer B   29mers
GAGCTCGTGCTGCTCGAATTCAAGCTTCT

3' SAGE Walking Primer / Linker sequences

MmeI-BseRI Linker A top   50 mers
5'-TTTGGATTTGCTGGTGCAGTACAACTAGGCGAGGAGCGTCTCTCCGACNN

10

MmeI-BseRI Linker A bottom   45 mers
5'phosphate-GTCGGAGAGACGCTCCTCGCCTAGTTGTACTGCACCAGCAAATCC
.

MmeI-BseRI Linker B top   50 mers
15   5'-TTTCTGCTCGAATTCAAGCTTCTAACGTACGAGGAGCGTCTCTCCGACNN

MmeI-BseRI Linker B bottom   45mers
5'phosphate-GTCGGAGAGACGCTCCTCGTACGTTAGAAGCTTGAATTCGAGCAG
PCR primer A   29mers
20   GTGCTCGTGGGATTTGCTGGTGCAGTACA

PCR primer B   29mers
GAGCTCGTGCTGCTCGAATTCAAGCTTCT

APPENDIX B: TABLE 1

Tag length n	Tag Complexity, C	Tag uniqueness to transcriptome, Ut	Tag uniqueness to human genome, Ug
4	256	1562	11718750
6	4096	146	732422
10	1048576	0.95	2861
14	268435456	0.0052	11
16	4294967296	0.00037	· 0.7
18	68719476736	0.000026	0.04
20	1099511627776	0.0000018	0.003

Table 1. Theoretical 5'tag complexity and uniqueness probability of matching to transcriptome and genome

C, the complexity of tags. $C = 4^n$, where n is the tag length. Short tags have less complexity and, therefore, are more frequent in a genome. The numbers indicate, in average, the size of sequence base pairs for a specific tag to occur once. For example a 6-bp tag will occur once in a genome every 4096 bp, while a 10-bp tag will appear only once in a one million bp sequence.

Ut, tag uniqueness to transcripts of a genome, is determined under the assumption that there are 100,000 distinct transcripts in a complex genome like human, mouse, or Zebrafish, and the 5'sequences of transcripts are random. $Ut = n*100,000/C$, indicates the number of transcripts that might share a same unique 5'tag.

Ug, the tag uniqueness to human genome. Ug is determined as the genome size (3,000,000,000 bp) divided by tag complexity. $Ug = Gs/C$, Gs is the genome size in bp. The numbers indicate the potential matches of a particular tag in the genome.

CLAIMS

1.   A method of obtaining a nucleotide sequence tag from a terminus of a nucleic acid, the method comprising the steps of:

(a) providing a first nucleic acid sequence;

5   (b) linking the first nucleic acid sequence to an linker sequence to form a linked nucleic acid, in which the linker sequence comprises:

(i) a first recognition site for a first nucleic acid cleavage enzyme that allows cleavage of the first nucleic acid sequence at a site distant from the first recognition site, and

10   (ii) a second recognition site for a second nucleic acid cleavage enzyme that allows nucleic acid cleavage at a site distant from the second recognition site, said cleavage site located at a position within or about the first recognition site;

in which the linked nucleic acid has the structure: 5' - second recognition site - first
15   recognition site - first nucleic acid - 3'

(c) cleaving the linked nucleic acid with the first nucleic acid cleavage enzyme to provide:

(i) a linked tag comprising the linker sequence linked to a nucleotide sequence tag representative of the first nucleic acid sequence and
20   comprising a terminal portion thereof; and

(ii) a second nucleic acid sequence comprising a remainder portion of the first nucleic acid.

2.   A method according to Claim 1, in which the first nucleic acid comprises a
complementary deoxyribonucleic acid (cDNA) having a terminus comprising a 5' terminal
transcribed sequence of a gene, and in which the linker sequence is linked to said terminus.

3.   A method according to Claim 1, in which the first nucleic acid comprises a

5   complementary deoxyribonucleic acid (cDNA) having a terminus comprising a 3' terminal
transcribed sequence of a gene, and in which the linker sequence is linked to said terminus.

4.   A method according to Claim 1, 2 or 3, in which the second nucleic acid cleavage
enzyme comprises a restriction endonuclease, preferably a Type IIS restriction
endonuclease, whose recognition site is 6 bases or greater, preferably MmeI.

10   5.   A method according to any preceding claim, in which the first nucleic acid
cleavage enzyme comprises a restriction endonuclease, preferably a Type IIS restriction
endonuclease, preferably BseRI.

6.   A method of sequentially generating a plurality of nucleic acid sequences each
comprising a nucleotide sequence tag from a nucleic acid, the method comprising

15   repeating steps (a) to (c) of any of Claims 1 to 5 at least once, in which the first nucleic
acid sequence of step (a) is provided by the second nucleic acid sequence of step (c)(ii).

7.   A method of providing an indication of an instance of expression of a gene, the
method comprising a method according to any preceding claim, and further comprising the
step of detecting the presence, sequence or identity of the linked tag or the nucleotide

20   sequence tag to provide an indication of an instance of gene expression.

8.   A method of detecting gene expression, the method comprising the steps of:

(a) providing a first linked tag and a second linked tag, each independently
produced by a method according to any preceding claim;

88

(b) linking the first linked tag and the second linked tag such that the nucleotide sequence tag portion of one linked tag is linked to the nucleotide sequence tag of the other linked tag to form a ditag, the ditag comprising terminal transcribed sequences from first and second genes; and

5   (c) detecting the presence or identity of the ditag, or at least one nucleotide sequence tag comprised therein, to detect gene expression.

9.   A method according to Claim 8, in which each of the first and second linker sequences comprised in the first and second linked tags comprises an amplification primer sequence, and in which the method further comprises a step of amplifying the ditag,
10   preferably by means of the polymerase chain reaction (PCR).

10.   A method according to Claim 8 or 9, further comprising the steps of:

(d) cleaving the ditag with the or each second nucleic acid cleavage enzyme;

(e) linking a plurality of the resultant trimmed ditags to form a concatamer; and

(f) obtaining the nucleic acid sequence of at least a portion of the concatamer.

15   11.   A method of providing an indication of an instance of expression of a gene, the method comprising the steps of:

(a) providing a complementary deoxyribonucleic acid (cDNA) having a terminus comprising a terminal transcribed sequence of a gene;

(b) linking the cDNA to an linker sequence thereby forming a linked nucleic acid,
20   in which the linker sequence comprises a first recognition site for a first nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site; and

(c) cleaving the linked nucleic acid with the first nucleic acid cleavage enzyme to provide a linked tag, in which the linked tag comprises a nucleotide sequence tag representative of a terminal transcribed sequence of the gene; and

(d) detecting the presence or identity of the linked tag or the nucleotide sequence

5   tag to provide an indication of an instance of gene expression.

12.   A method according to Claim 10, in which the 5' end of the cDNA comprises a sequence corresponding to the 5' terminal transcribed sequence of the gene, and in which the linker sequence is linked to the 5' end of the cDNA.

13.   A method according to Claim 11 or 12, in which the nucleotide sequence tag

10   comprises a 5' terminal transcribed sequence of the gene, preferably at least the first 16 bases of the transcribed portion of the gene, more preferably the first 20 bases of the transcribed portion of the gene.

14.   A method according to Claim 11, in which the 3' end of the cDNA comprises a sequence corresponding to the 3' terminal transcribed sequence of the gene, and in which

15   the linker sequence is linked to the 3' end of the cDNA.

15.   A method according to Claim 11 or 14, in which the nucleotide sequence tag comprises a 3' terminal transcribed sequence of the gene, preferably at least the last 16 bases of the transcribed portion of the gene, more preferably the last 20 bases of the transcribed portion of the gene.

20   16.   A method according to Claim 11, 14 or 15, in which step (a) comprises:

(i) deriving a cDNA from an mRNA by reverse transcription with an primer comprising a sequence 5'-NV(T)^{13}CCGGCCGG-3', in which N = A, C, G or T and V = A, C or G;

(ii) producing a double stranded cDNA therefrom and digesting the double stranded cDNA with FseI to produce a cleaved cDNA comprising

$$3' \frac{\text{GGCCGG}}{\text{CC}} \text{ overhang;}$$

(iii) linking the cleaved cDNA to a linker comprising $\dfrac{\text{pTCGGA}}{\text{GGCCAGCCT}}$; and

5   (iv) cleaving the resulting molecule with MmeI to produce a cDNA lacking a polyA/T tail.

17.   A method according to any of Claims 11 *et seq*, in which the cDNA comprises the 5' terminal transcribed sequence of the gene, or the 3' terminal transcribed sequence of the gene, or both.

10   18.   A method according to any preceding of Claims 11 *et seq*, in which the cDNA is full length cDNA, preferably comprising substantially all the coding sequence of the gene.

19.   A method of obtaining sequential sequence information from a gene, the method comprising steps (a) to (c) of a method according to Claim 11, or any claim dependent thereon, the method further comprising:

15   (d) providing a second nucleic acid from step (c) comprising 3' remaining sequences of the cDNA;

          (e) linking the second nucleic acid to an linker sequence, thereby forming a linked nucleic acid, in which the linker sequence comprises a recognition site for a nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic
20   acid cleavage at a site distant from the recognition site;

          (f) cleaving the linked nucleic acid with the nucleic acid cleavage enzyme to provide: (i) a linked tag comprising the linker sequence linked to a nucleotide sequence tag comprising a 5' portion of the second nucleic acid; and (ii) a fourth nucleic acid sequence comprising a 3' remainder portion of third nucleic acid;

(g) repeating steps (d) to (f) at least once, in which the second nucleic acid
sequence of step (d) is provided by the fourth nucleic acid sequence of step (f)(ii);
and

(h) detecting the presence, identity or sequence of at least one linked tag or a
nucleotide sequence tag comprised therein.

20.   A method according to any of Claims 11 *et seq*, in which the linker sequence
further comprises a second recognition site for a second nucleic acid cleavage enzyme,
preferably a second restriction endonuclease, that allows nucleic acid cleavage at a site
distant from the second recognition site, and in which the second recognition site is located
5' of the first recognition site in the linker sequence.

21.   A method according to Claim 20, in which the location of the second recognition
site with respect to the first recognition site is such that, when the linked tag is exposed to
the second nucleic acid cleavage enzyme, cleavage of the nucleic acid occurs at a position
within or about the first recognition site.

22.   A method according to any of Claims 11 *et seq*, in which the first recognition site
or the second recognition site, or both, comprises a Type IIS restriction enzyme
recognition site.

23.   A method according to any of Claims 11 *et seq*, in which the first restriction
enzyme comprises Mme1, or in which the first recognition site comprises a Mme1
recognition site 5'-TCC RAC-3', preferably 5'-TCC GAC-3'.

24.   A method according to Claim 22 or 23, in which the second restriction enzyme
comprises a restriction enzyme capable of recognising a site which is 6 bases or longer,
preferably BseR1, or in which the second recognition site comprises a BseRI recognition
site 5'-GAGGAG-3'.

25.   A method according to any of Claims 11 *et seq*, in which the linker sequence comprises the sequence 5'-GAGGAGNNNNNNTC CG AC -3', preferably 5'-GAGGAGCGTCTCTCCGAC-3'.

26.   A method of detecting expression of a gene, the method comprising:

5   (a) providing a first linked tag and a second linked tag, each independently produced by a method according to any preceding claim;

            (b) linking the first linked tag and the second linked tag such that the nucleotide sequence tag portion of one linked tag is linked to the nucleotide sequence tag of the other linked tag to form a ditag, the ditag comprising terminal transcribed
10   sequences from first and second genes; and

            (c) detecting the presence or identity of the ditag, or at least one nucleotide sequence tag comprised therein, to detect gene expression.

27.   A method according to Claim 26, in which each of the first linker sequence of the first linked tag and the second linker sequence of the second linked tag comprises an
15   amplification primer hybridisation sequence.

28.   A method according to Claim 27, in which the method further comprises a step of amplifying the ditag, preferably by means of the polymerase chain reaction (PCR).

29.   A method according to any of Claims 26 to 28 as dependent on any of Claims 20 to 25, which further comprises the step of cleaving the ditag with the or each second nucleic
20   acid cleavage enzyme to provide a trimmed ditag.

30.   A method according to any of Claims 26 to 29, in which the trimmed ditag comprises between 12 to 120 base pairs, preferably between 18 to 46 base pairs, preferably 40 base pairs.

31.   A method according to any of Claims 26 to 30, in which a plurality of ditags or
trimmed ditags are linked to form a concatamer.

32.   A method according to any of Claims 26 to 31, in which the concatamer comprises
between 2 to 200 ditags or trimmed ditags, preferably between 10 to 40 ditags or trimmed
5   ditags, preferably between 8 to 20 ditags or trimmed ditags.

33.   A method according to any of Claims 11 *et seq*, further comprising the step of
determining the sequence of a or each linked tag, nucleotide sequence tag, ditag, trimmed
ditag or concatamer.

34.   A method according to Claim 33, further comprising the step of determining the
10   identity of the expressed gene by the comparing the sequence to a nucleotide sequence
comprised in a database of nucleotide sequences.

35.   A method according to Claim 33 or 34, in which the sequence is compared to a
database of known genes, such that if the database does not comprise the sequence, the
sequence comprises a new gene.

15   36.   A method of providing an indication useful in the diagnosis of a disease in an
individual, the method comprising:

        (a) providing a cell known to be affected by the disease;

        (b) determining if a gene is expressed in the cell of (b) by a method according to
        any preceding claim;

20   (c) providing a cell of an individual suspected of suffering from the disease; and

        (d) determining whether the same gene is expressed in the cell of (c) by a method
        according to any preceding claim; and

94

(e) comparing the expression, or lack thereof, of the gene between the cell of (b) and the cell of (c).

37.   A method of producing determining the transcriptome of a cell, or obtaining a gene expression profile of a cell, the method comprising providing cDNA from the cell,

5   subjecting said cDNA to a method according to any preceding claim, and determining whether a particular gene, or a particular set of genes, is expressed by the cell.

38.   A method of providing an indication useful in the diagnosis of a disease in an individual, the method comprising comparing the gene expression profile of a cell known to be affected by the disease, with a cell of an individual suspected of suffering from the

10   disease, in which either or both of the gene expression profiles are produced by a method according to Claim 37.

39.   A method of determining the sequence of a control sequence of a gene, preferably a promoter or enhancer sequence, the method comprising:

(a) obtaining a nucleotide sequence tag representative of the 5' terminal transcribed

15   sequence of the gene by a method according to Claims 1, 2, or 3, or any claim dependent thereon; and

(b) obtaining a sequence of the gene 5' to the terminal transcribed sequence of (a), in which the sequence comprises a promoter or enhancer consensus sequence.

40.   A method according to Claim 39, in which the sequence of the gene 5' to the

20   terminal transcribed sequence of (a) is obtained by means of (a) chromosome walking, (b) SAGE walking, (c) nucleic acid hybridisation of a genomic library; or (d) querying a database of genomic sequences.

41.   A database comprising a plurality of records, each record comprising an indication whether a gene is expressed by a particular cell, which indication is provided by a method

25   according to any preceding claim.

42.   A computer readable medium comprising a database according to Claim 41.

43.   A nucleic acid sequence comprising a tag produced by a method according to any of Claims 1 to 25.

44.   A nucleic acid sequence comprising a ditag produced by a method according to any
5   of Claims 1 to 30.

45.   A nucleic acid sequence comprising a concatamer comprising a plurality of tags according to Claim 43 or a plurality of ditags according to Claim 44.

46.   A gene identified by a method according to Claim 35, or a protein encoded by the gene.

10   47.   A control sequence, preferably a promoter sequence, identified by a method according to Claim 40.

48.   A nucleic acid sequence comprising: (a) a recognition site for a nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site, and (b) a nucleotide sequence tag
15   representative of a terminal transcribed sequence of a gene.

49.   A nucleic acid sequence according to Claim 48, further comprising: (c) a second recognition site in which the second recognition site is for a second nucleic acid cleavage enzyme, preferably a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site, and in which the cleavage site for the
20   second nucleic acid cleavage enzyme is located within or about the first recognition site.

50.   A linker sequence comprising:

(a) a first recognition site for a nucleic acid cleavage enzyme, preferably a restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site;

(c) a second recognition site for a second nucleic acid cleavage enzyme, preferably a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site;

in which in which the cleavage site for the second nucleic acid cleavage enzyme is located within or about the first recognition site.

51.   A nucleic acid according to Claim 49, or a linker sequence according to Claim 50, in which the first recognition site and the second recognition site are spaced such that when the nucleic acid is exposed to the second nucleic acid cleavage enzyme, cleavage of the nucleic acid occurs at a position within the first recognition site.

52.   A nucleic acid according to any of Claims 48 to 51, in which the nucleic acid sequence comprises the sequence 5'-GAGGAGNNNNNNTC CG AC -3', preferably 5'-GAGGAGCGTCTCTCCGAC-3'.

51.   A method for detecting expression of a gene, the method comprising the steps of:

(a) providing a first complementary deoxyribonucleic acid (cDNA) having a terminus comprising a terminal transcribed sequence of a first gene;

(b) providing a second complementary deoxyribonucleic acid (cDNA) having a terminus comprising a terminal transcribed sequence of a second gene;

(c) linking the first cDNA so produced to a first linker sequence thereby forming a first linked nucleic acid, in which the first linker sequence comprises a first recognition site for a first nucleic acid cleavage enzyme, preferably a first restriction endonuclease, that allows nucleic acid cleavage at a site distant from the first recognition site;

(d) linking the second cDNA so produced to a second linker sequence thereby forming a second linked nucleic acid, in which the second linker sequence comprises a second recognition site for a second nucleic acid cleavage enzyme, preferably a second restriction endonuclease, that allows nucleic acid cleavage at a site distant from the second recognition site;

(e) cleaving the first linked nucleic acid with the first nucleic acid cleavage enzyme to provide a first linked tag, in which the first linked tag comprises a first nucleotide sequence tag representative of a terminal transcribed sequence of the first cDNA.

(f) cleaving the second linked nucleic acid with the second nucleic acid cleavage enzyme to provide a second linked tag, in which the second linked tag comprises à second nucleotide sequence tag representative of a terminal transcribed sequence of the second cDNA.

(g) ligating the first and second tags to form a ditag; and

(h) determining the nucleotide sequence of at least one tag of the ditag to detect gene expression.

52.   A nucleotide sequence tag obtainable by a method according to any preceding claim.

53.   A method of obtaining a nucleotide sequence tag substantially as hereinbefore described with reference to and as shown in Figures 2 to 4 of the accompanying drawings.

54.   A method of detecting gene expression substantially as hereinbefore described with reference to and as shown in Figures 2 to 4 of the accompanying drawings.

55.   A method of 5' Terminal SAGE substantially as hereinbefore described with reference to and as shown in Figure 3 of the accompanying drawings.

56.   A method of 3' Terminal SAGE substantially as hereinbefore described with reference to and as shown in Figure 4 of the accompanying drawings.

FIG. 1A

FIG. 1B

FIG. 2

FIG. 3

FIG. 3 CONT'D

FIG. 4

FIG. 4 CONT'D

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   C12Q1/68   C12N15/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   C12Q   C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, EMBASE, BIOSIS, MEDLINE, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/10438 A (JOHNS HOPKINS UNIVERSITY) 7 February 2002 (2002-02-07) cited in the application	1,4-10, 26-40,48
A	abstract; claims 3,17,41,52,71,74,75,97	2,3, 49-53
	paragraph '0020!; figures 1,5 ---	
X	US 5 710 000 A (GINGERAS T.R. ET AL.) 20 January 1998 (1998-01-20)	48-51
A	abstract; claims 1-11; figures 1-3	1-40,52, 53

	-/--	

[X]	Further documents are listed in the continuation of box C.	[X]	Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 April 2004	17/05/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Barz, W

Form PCT/ISA/210 (second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 13 June 2002 (2002-06-13) "Tetraodon nigroviridis clone GSTNB-42J2, 14 unordered pieces" retrieved from EBI Database accession no. AC124167 XP002278593 positions 15123-15140	48-52
X	WO 01/48247 A (ARCH DEV CORP) 5 July 2001 (2001-07-05)	1,4-10, 26-40
A	abstract; claims 1-41; figures 1,5	2,3, 48-53
X	EP 0 761 822 A (UNIV JOHNS HOPKINS MED) 12 March 1997 (1997-03-12) cited in the application	1,4-10, 26-40
A	abstract; claims 20-40	2,3, 48-53
X	US 6 383 743 B1 (KINZLER K.W. ET AL) 7 May 2002 (2002-05-07) cited in the application	1,4-10, 26-40
A	abstract	2,3, 48-53
A	US 5 981 190 A (ISRAEL D.I.) 9 November 1999 (1999-11-09) abstract	1-40,53
A	US 6 136 537 A (MACEVICZ S.C.) 24 October 2000 (2000-10-24) abstract; claims 1-8	1-40,53
A	CHEN J.-J. ET AL.: "Generation of longer cDNA fragments from serial analysis of gene expression tags for gene identification" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 1, 4 January 2000 (2000-01-04), pages 349-353, XP002196426 ISSN: 0027-8424 abstract; figure 1	1-40,53

-/--

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RYO A. ET AL.: "A modified serial analysis of gene expression that generates longer sequence tags by nonpalindromic cohesive linker ligation" ANALYTICAL BIOCHEMISTRY, vol. 277, no. 1, 1 January 2000 (2000-01-01), pages 160-162, XP002260215 ISSN: 0003-2697 the whole document	1-40,53
A	YAMAMOTO M. ET AL.: "Use of serial analysis of gene expression (SAGE) technology" JOURNAL OF IMMUNOLOGICAL METHODS, vol. 250, no. 1-2, 1 April 2001 (2001-04-01), pages 45-66, XP004230694 ISSN: 0022-1759 the whole document	1-40,53
A	VELCULESCU V.E. ET AL.: "CHARACTERIZATION OF THE YEAST TRANSCRIPTOME" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 88, 24 January 1997 (1997-01-24), pages 243-251, XP002070903 ISSN: 0092-8674 cited in the application abstract; figure 1	1-40,53
A	VELCULESCU V.E. ET AL.: "SERIAL ANALYSIS OF GENE EXPRESSION" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 270, no. 5235, 20 October 1995 (1995-10-20), pages 484-487, XP001024449 ISSN: 0036-8075 the whole document	1-40,53

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SG 03/00255

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 41-42
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

2. [X] Claims Nos.: 46-47, 54-58
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest   [ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

Continuation of Box I.1

Although claim 36 is directed to a diagnostic method comprising a potential surgical step ("providing a cell..."), the search has been carried out and based on diagnostic methods lacking such a surgical step.

Continuation of Box I.1

Claims Nos.:   41-42

Claim 41 has not been searched, because it relates to a database, i.e. the mere presentation of information (Rule 39.1(v) PCT). Similarly, claim 42 also has not been searched, because its computer-readable medium is only defined by the database of claim 41.

Continuation of Box I.2

Claims Nos.:   46-47, 54-58

Claim 46 relates to genes defined only by the method of their identification ("identified by a method according to claim 35") and not by any technical features (i.e. by any sequence of said genes). Since the skilled person is unable to determine which sequences fall under the wording of said claim, lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible.

Similar objections apply to the control sequences of claim 47, because they are defined only the method of their identification and not by technical features. Therefore, the skilled person is unable to understand which nucleic acid sequences fall under the wording of said claim. Consequently, claim 47 has not been searched.

Finally, the last five claims of the present application (termed "52"-"56" which correspond to the 54th to 58th claim of the application) cannot be searched for the following reasons:

The 54th claim of the application (i.e. the second claim having the number "52") relates to nucleotide sequence tags defined by reference to the procedure of their production ("obtainable by a method according to any preceding claim"). Since, however, said claim does not contain any technical features defining said tags (i.e. their sequences), the skilled person is not in the position to clearly and unambiguously determined the nature of said tag. Therefore, a meaningful search is impossible for said claim.

Finally, the last four claims of the application (termed "53"-"56") also cannot be searched, because the expression "substantially as hereinbefore

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

described with reference to and as shown in Figure '...! of the
accompanying drawings" is not sufficient to define the methods of said
claims by technical features. Furthermore, said claims are not concise,
because they are redundant to other method claims of the present
application. Therefore, said claims lack clarity and conciseness in the
sense of Article 6 PCT to such an extent as to render a meaningful search
of the claim impossible.

The applicant's attention is drawn to the fact that claims, or parts of
claims, relating to inventions in respect of which no international
search report has been established need not be the subject of an
international preliminary examination (Rule 66.1(e) PCT). The applicant
is advised that the EPO policy when acting as an International
Preliminary Examining Authority is normally not to carry out a
preliminary examination on matter which has not been searched. This is
the case irrespective of whether or not the claims are amended following
receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/SG 03/00255

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0210438	A	07-02-2002	AU	8087501 A	13-02-2002
			WO	0210438 A2	07-02-2002
			US	2003008290 A1	09-01-2003
US 5710000	A	20-01-1998	US	6027894 A	22-02-2000
			US	2003059815 A1	27-03-2003
			US	6291181 B1	18-09-2001
			US	2003008292 A1	09-01-2003
WO 0148247	A	05-07-2001	AU	2743001 A	09-07-2001
			CA	2395920 A1	05-07-2001
			EP	1254257 A2	06-11-2002
			WO	0148247 A2	05-07-2001
			US	2003104369 A1	05-06-2003
EP 0761822	A	12-03-1997	US	5695937 A	09-12-1997
			US	5866330 A	02-02-1999
			AT	239093 T	15-05-2003
			AU	707846 B2	22-07-1999
			AU	6561496 A	20-03-1997
			AU	7018896 A	01-04-1997
			CA	2185379 A1	13-03-1997
			DE	69627768 D1	05-06-2003
			DE	69627768 T2	08-04-2004
			DE	761822 T1	11-01-2001
			DK	761822 T3	18-08-2003
			EP	1231284 A2	14-08-2002
			EP	0761822 A2	12-03-1997
			ES	2194957 T3	01-12-2003
			GB	2305241 A ,B	02-04-1997
			IE	80465 B1	12-08-1998
			JP	10511002 T	27-10-1998
			JP	3334806 B2	15-10-2002
			JP	2001155035 A	08-06-2001
			JP	2001145495 A	29-05-2001
			WO	9710363 A1	20-03-1997
			US	2003049653 A1	13-03-2003
			US	6383743 B1	07-05-2002
US 6383743	B1	07-05-2002	US	5866330 A	02-02-1999
			US	5695937 A	09-12-1997
			US	2003049653 A1	13-03-2003
			AT	239093 T	15-05-2003
			AU	707846 B2	22-07-1999
			AU	6561496 A	20-03-1997
			AU	7018896 A	01-04-1997
			CA	2185379 A1	13-03-1997
			DE	69627768 D1	05-06-2003
			DE	69627768 T2	08-04-2004
			DE	761822 T1	11-01-2001
			DK	761822 T3	18-08-2003
			EP	1231284 A2	14-08-2002
			EP	0761822 A2	12-03-1997
			ES	2194957 T3	01-12-2003
			GB	2305241 A ,B	02-04-1997
			IE	80465 B1	12-08-1998
			JP	10511002 T	27-10-1998
			JP	3334806 B2	15-10-2002

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 6383743	B1		JP	2001155035 A	08-06-2001
			JP	2001145495 A	29-05-2001
			WO	9710363 A1	20-03-1997
US 5981190	A	09-11-1999	NONE		
US 6136537	A	24-10-2000	US	6054276 A	25-04-2000
			US	6720179 B1	13-04-2004